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Biological and environmental factors contribute collectively to the 
development of human cancers. The primary focus of this research project 
was to investigate the impact of germline gene mutations, as a significant 
biological factor, on 29 major primary human cancers. For this I obtained 
data from multiple databases, including the Genetic Association Database 
(GAD), Sanger database (COSMIC), HGMD database, OMIM data and 
PubMed literature. Using the Extraction Transform and Load (ETL) 
process, 424 genes were obtained with 8,879 cancer mutation records. By 
integrating these gene mutation records a Human Cancer Map (HCM) was 
constructed, from which several sub-maps were derived based on 
particular mutation classes. Furthermore, a Protein-Protein Interaction 
Map (PPIM) was constructed based on the encoded proteins of the 424 
gene set.  
  
Several key questions were addressed using the HCM and its sub-maps 
including the following: (i) Are individual groups of primary cancers 
associated with specific subset of genes (within the 424 full set)? (ii) Are 
groups of primary cancers associated with particular mutation classes? (iii) 
If both questions prove to be true, are groups of cancers associated with 
particular mutation class of target genes? This project also explored 
whether a corresponding Protein-Protein Interaction Map, derived from the 
Missense/Non-sense Mutation portion of the HCM gene set, would provide 
further information on gene associations between primary cancers in 
terms of the consequent identical amino acid changes involved.   
 
Results showed that: (1) closely-connected human cancers in the HCM 
exhibited a strong association with a particular mutation class;  (2) 
Missense /Nonsense and Regulatory mutations played a central role in 
connecting cancers (i.e. via primary nodes) and so significantly influenced 
the construction of the HCM; (3) Genes with Missense/Nonsense and 
Regulatory mutations tended to be involved in cancer-associated 
pathways; (4) Using the kappa test to measure the extent of agreement 
between two connected primary cancers in the sub-HCMs, BRCA1, 
BRCA2, PALB2, MSH2, MSH6, MLH1, CDKN2A, and TP53 showed 
   
 II 
highest agreement for 5 of 10 mutation classes; (5) From the PIPM, it was 
evident that BRCA1, MSH6, BARD1, TP53, MSH2 and CHEK2 proteins 
best connected Breast, Ovarian, Prostate and Bowel primary cancers, and 
so the latter could represent ‘driver proteins’ for these cancers.   
 
In summary, this project has approached the analysis of gene involvement 
in human primary cancers from the starting position of the mutation class 
that harbours the specific gene mutation. Together with their downstream 
resultant alterations in the associated proteins, this analysis can provide 
insights into the relatedness of primary human cancers and their potential 
gene hierarchies. These data may therefore help us to understand more 
fully the etiology, diagnosis and potentially personalized treatments for 
cancer.  
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Chapter One  
 
1. Fundamentals of Genes in Health and Disease 
 
Until recently the approach most widely used to investigate the 
fundamentals of human genetic variations in relation to the progression of 
human health and diseases has been focused primarily on identifying the 
variations of an individual candidate gene with the described patterns of 
Mendelian inheritance disease. The origin of Mendelian patterns of 
inheritance disease was first proposed by Gregor Mendel in 1865, on the 
basis of dominant and recessive genes (Mendel, 2008). Humans carry two 
copies of the same gene, each one of these copies is inherited from both 
parents. If one of the inherited gene copies is mutated on one of the 
autosomal chromosomes  (chromosomes 1-22) it can lead to the 
development of diseases, such as Huntington’s disease (Griffiths, 2005), 
neurofibromatosis type 1,2 and hereditary non-polyposis colorectal cancer 
etc. This is known as autosomal dominant. if both copies of the inherited 
genes from both parents are mutated then this can be called autosomal 
recessive, which is evident in newly born babies and certain rare 
conditions like cystic fibrosis (Flotte and Laube, 2001), sickle-cell disease 
and Tay-Sachs disease. Otherwise, if one copy of the mutated gene 
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occurs on the X chromosome, this can be called ‘X-linked dominant’ when 
the mutated gene is acting in dominant manner. The impact of the mutated 
gene can have influence on causing a disease in both males and females 
(as both genders have an X-chromosome), like Incontinentia pigment 
disease (Meuwissen and Mancini, 2012). If both gene copies are mutated 
this is known to be ‘X-linked recessive’ leading to disorders including 
Duchenne muscular dystrophy (Moat et al., 2013), or the less serious red-
green colour blindness (Lenaers et al., 2012) and male pattern baldness. 
Finally, if the mutated gene occurs on the Y chromosome, this can be 
called ‘Y-linked’, which is implicated for males only, and is known to be 
associated with male infertility (Yang and Zhang, 2010).  
Secondly, genetic heterogeneity influenced by environmental 
factors, i.e., etiologic heterogeneity, is associated with multiple groups of 
diseases that occur in populations e.g., breast cancers (Ford et al., 1998). 
Identifying the etiologic heterogeneity can be an important step toward 
detecting the possible impacts of gene-gene and gene-environment 
interactions on disease progression.  A third approach for consideration is 
to identify the influence caused by a group of genes on each other leading 
to the presentation or expression of diseases. Systems biologists have 
shown that diseases that share phenotypic similarity are often associated 
with genes with strong functional associations (Oti et al., 2008). Also, 
genes associated with similar functions tend to have similar expression 
patterns (Chu et al., 1998), which provide us with an opportunity to gain 
insight into the functional association of genes. These valuable insights 
have opened up the potential for a virtual roadmap for physicians, genetic 
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counsellors and biomedical researchers for the further study of disease 
associations and will help our understanding of how diseases are caused 
and so may be successfully treated. 
1.1. Chromosomes 
 
There are 23 pairs of different chromosomes in human cells, with 
one member of each pair inherited from each parent. One of these pairs 
represents the so-called sex chromosomes, with either two X or one X and 
one Y chromosome. Only the father can contribute the Y chromosome to 
produce a male offspring, while both parents can contribute an X 
chromosome to produce a female child discussed in (Pasternak, 2005).  
Eukaryotic chromosomes are mixtures of DNA and proteins, which 
together are called chromatin (Figure 1.1). A small amount of RNA is also 
present. Two classes of proteins, called histones and non-histone (or 
acidic) proteins are present to play a central role in chromatin structure. 
Proteins that form histones have a highly conserved amino acid sequence, 
suggesting that these molecules are very important. The basic building 
block of chromatin structure is called the nucleosome (Parry, 2001; Brown, 
1992).  
Nucleosomes consist of a core of histones around which DNA is wound. 
The core of DNA consists of two discs arranged in parallel, each 
composed of four histone molecules. The linker length between the 
nucleosomes varies. In humans it is about 60 base pairs (bp), giving a 
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Figure 1.1: An Illustration of a Chromosome. Each chromosome is divided into 
two parts by a point known as a ‘Centromere’. Chromosomes consist of four 
arms, two is known as short arms, labelled as ‘p,’ and the other two known as 




The DNA molecule consists of three basic components: pentose 
sugar, (i.e, deoxyribose) and a phosphate group, as well as four types of 
nitrogenous bases, of which cytosine and thymine are single carbon-
nitrogen rings (called pyrimidines), and adenine and guanine are double 
carbon-nitrogen rings (called purines). It is important to note that the four 
bases combine with hydrogen ions in acidic solutions (Parry, 2001; 
Roberts and Pembrey, 1970; Brown, 1992). The chemical structure of the 
four bases that constitute the DNA molecule is shown in figure 1.2. There 
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are three hydrogen bonds between the cytosine-guanine pairs, whereas 
there are two hydrogen bonds between the adenine-thymine pairs (Parry, 
2001; Roberts and Pembrey, 1970; Brown, 1992).  
 
 
Figure 1.2: Chemical structure of the DNA molecule. From (Wikipedia, 
http://en.wikipedia.org/wiki/File:DNA_chemical_structure.svg). 
 The double helix DNA molecule contains sugar-phosphates, which are held 
together in order to form the backbone of the polynucleotide strands. It is 
important to note that the polynucleotide chains run in opposite directions so that 
the polynucleotide has a free 5’ phosphate at one end and a free 3’ OH at the 
other end. The sequence of bases encoding the genetic information is read as 5’ 
to 3’ or 3’ to 5’. The four nitrogenous bases face the inner surface of each strand; 
hydrogen ties the four nitrogenous bases in the DNA strands, which creates the 
double helix. Each DNA subunit consists of one deoxyribose, one phosphate 
group and one base, called a nucleotide. Different sequences of nucleotide 
bases (ACCAAGTGC) specify a code for different proteins. Every 10 nitrogenous 
bases is executed to form the double helix. The sequence of base paring is 
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restricted such that adenine can only pair with thymine and guanine, can only 
pair with cytosine. This is called Complementary Base Pairing. This allows 
genetic information to be preserved during replication of the DNA and expression 
of the gene (Parry, 2001; Roberts and Pembrey, 1970; Brown, 1992; Lodish et 
al., 2000), as shown in figure 1.3. 
 
Figure 1.3: DNA and its building blocks. From (Lodish et al., 2000). 
1.3. Genes 
 
The DNA provides biological information for the organism, which 
will be encoded in a base sequence of the DNA and structured as an 
enormous number of genes. Individually these contain the instructions for 
the synthesis of a polypeptide (i.e. protein). From a physical perspective, a 
gene is a distinct segment of DNA with a base sequence that instructs the 
amino acid sequence of a polypeptide (Brown, 1992).  
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Genes differ significantly in size (the number of base pairs), ranging from 
less than 100 base pairs to several million base pairs. In higher-level 
organisms, the genes are run in a sequence of extremely long DNA 
molecules, named chromosomes. In humans there are around 20,000 to 
25,000 genes, organized in 23 chromosomes (Quackenbush, 2011).  
Biological information is carried by one of the two strands of the DNA 
double helix, which is known as the template/non coding/antisense strand, 
and can be used to generate an RNA molecule of the matching sequence, 
to direct the synthesis of the corresponding polypeptide. Whereas the term 
‘gene’ is often applied to the non-template/coding/sense strand, which 
allow the RNA polymerase reads and transcribes into mRNA, for a 
transcription into mRNA to occur a promoter sequence must be in the 
correct orientation position (Pasternak, 2005). 
1.4. Genetic Code 
The genetic code, as shown in Figure 1.4, illustrates how base 
sequences are transformed into amino acid sequences, where the DNA 
sequence of a gene is separated into units of three nucleotides. A 
nucleotide is composed of a base, a five-carbon sugar (either ribose or 2'-
deoxyribose) and a phosphate group. Each triplet nucleotide is called a 
codon and is indicative of a particular amino acid. Exceptions include 
methionine and tryptophan, which can be encoded by more than one 
codon (Figure 1.4). 
Codons that specify the same amino acid are called synonym codons and 
tend to be very similar; for example ACU, ACC, ACA and ACG, where the 
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changes are all at the third position of the codon  - called the “wobble 
position” (Brown, 1992; Hames and Hooper, 2000). Uracil is one of the 4 
bases in the nucleic acid of RNA. 
The genetic code is said to exhibit degeneracy. This is a description of 
redundancy, but without ambiguity. For example, although codons GAA 
and GAG both specify glutamic acid (an example of redundancy), neither 
of them specifies any other amino acid (therefore no ambiguity). 
Degeneracy of the genetic code minimizes the effects of mutations so that 
alterations to the base sequence are less likely to change the amino acid 
encoded with possible deleterious effects on protein function. It is 
important to note that there are 64 possible codons. 61 of these encode 
amino acids, while the remaining three codons (TAA, TAG, and TGA) act 
as signals for protein synthesis, which are known as termination codons or 
stop codons. The codon for methionine signals protein synthesis to start, 
and is known as the initiation codon (Brown, 1992) (Figure 1.4). 
 
Figure 1.4: Genetic codes, where the letters T, C, A and G are the actual base  
letters and the abbreviation letters after the codons is the produced amino acid 
from each codon (Brown, 1992). 
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The term Genotype describes the genetic or specific allele makeup 
of an individual and so also can inform the mutation types of specific 
genes under assessment. The Phenotype describes the individual’s 
observable characteristics or traits (e.g. morphology or other biochemical 
or physiological properties, behaviour etc.). Thus, genetic mutation can 
result in phenotypic change. Different forms of mutations include: 
Regulatory, Complex rearrangements, Gross deletions, Gross 
Insertions, Missense/Nonsense, Repeat Variations, Small deletions, 
Small indels, Small insertions and Splicing variants (Joshi, 1997). 
These genetic mutations can give rise to several possibilities of human 
diseases when function is negatively affected.  
Mutations can occur due to errors during DNA replication or be caused by 
environmental factors, such as a chemical mutagen, cosmic radiation, 
chemical carcinogenic, virogenic and ionic radiation. Environmental factors 
can have effects on human health and cause variance at the gene level, 
especially in cases of somatic cell mutation (Figure 1.5). This figure 
illustrates the intrinsic factors that cause genetic mutations in the human 
genome; either via an error occurring during DNA replication or 
methylation or via a transposable genetic element. By contrast, extrinsic 
factors (e.g., physical, chemical and cosmic radiation) can also cause 
gene mutations.   
Besides errors in a DNA replication, gene mutations can be caused by 
various events: - 
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 If the gene-coding region is affected this could lead to alteration of the 
amino acid sequence in the resultant polypeptide chain of a specific 
protein (Kimball, 2003).  
 Methylation, known as the biochemical process for adding the methyl 
group to the cytosine or adenine DNA nucleotides. Whereas the 
Transposable Genetic Element is the DNA sequence that can change 
its position within the genome. These two terms can also give rise to 
abnormal gene products, which can behave like gene mutations. 
However both sometimes only provide temporary prevention of normal 
gene expression, that leads to modification of phenotypic performance, 
known as the epigenetic effect (Kimball, 2003). 
 Epigenetics is the modification to the genome of cancer cells, which is 
caused by a number of factors (e.g., methylation), and usually occurs 
due to methylation at the cytosine base (CpG). The epigenetic change 
does not involve nucleotide sequence changes, and it is as important 
as genetic mutations in a cell’s transformation to cancers (Novak, 
2004).  
Furthermore, a gene mutation is a change in DNA sequence away from 
‘normal’ to abnormal genetic variance. In contrast, a polymorphism is a 
common variation in DNA sequence among individuals in a population. To 
distinguish a mutation from a polymorphism, there is an arbitrary cut-off 
point observed as ≥ 1% prevalence in a population. If this found to be < 
1% then the allele is regarded as a mutation (Ahmadian et al., 2000). 
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Figure 1.5: Causes of Genetic mutations. 
 
1.6. Gene Mutation Classes 
1.6.1. Frame Shift Mutation (Insertions and Deletions) 
 
A frame shift mutation involves the deletion or insertion of a single 
nucleotide, which results in extra or missing amino acids in a polypeptide 
chain of a protein, with the possibility of having a deleterious effect. 
Deletions and insertions tend to be especially harmful when the number of 
missing or extra base pairs is not a multiple of three. This is due to the fact 
that codons consist of groups of three base pairs and such insertions or 
deletions can alter all of the downstream codons (Bell et al., 2003). See 
the example figures 1.6 and 1.7 for single base insertion and deletion. 
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Figure 1.6: The insertion of single base (an A in the second codon) would convert 
the DNA sequence so it reads as 5’-CAT CAT CATCATCATCAT CAT-3’ To 5’-
CAT CAT CAT ACA TCA TCA TCA-3’. This would change the amino acid 
sequence from His-His-His-His-His-His-His to His-His-His-Thr-Ser-Ser-Ser. 
Image  from (Medicine, 2013b) 
 
 
Figure 1.7: The deletion of single base (an A in the second codon) would convert 
the DNA sequence so it reads as 5’-CAT CAT CATCATCATCAT CAT-3’ To 5’-
CAT CAT CAT CTC ATC ATC ATC-3’. This would change the amino acid 
sequence from His-His-His-His-His-His-His to His-His-His-leu-lle-lle-lle.  Image 
taken from (Medicine, 2013a) 
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1.6.2. Missense/Nonsense Mutation 
Missense mutations involve a change in a single amino acid that 
may affect a protein’s structure or function, and is thus likely to lead to a 
harmful effect in the individual and to generate a mutant phenotype 
(Kozak, 1986). Nonsense mutations can produce, in error, one of three 
stop codons (UAA, UAG or UGA) in messenger RNA (mRNA). The stop 
codons can terminate both mRNA transcription and translation and so 
result in premature termination of the polypeptide chain. On the other 
hand, if a correct stop codon is altered to now encode for an amino acid, 
an abnormally elongated polypeptide is then produced (Welch et al., 2007) 
(Figure 1.8).  
 
Figure 1.8: Missense mutations, of single base (an A in the 4th codon) would 
convert a DNA sequence so it reads as 5’-CAT CAT CAT CAT CAT CAT CAT-3’ 
to 5’-CAT CAT CAT CCT CAT CAT CAT-3’. This would change the amino acid 
sequence from His-His-His-His-His-His-His to His-His-His-Pro-His-His-His. 
Image Taken from (Medicine, 2013c) 
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1.6.3. Splice Site Mutation 
Various types of RNA molecules play key roles in making proteins. 
The gene transcript (mRNA) transfers information from DNA in the 
nucleus to the ribosome in the cytoplasm that makes protein. The mRNA 
molecule is used in protein formation via a process called RNA splicing via 
the excision of Introns (non-coding elements) and re-connecting the Exons 
together (see figure 1.9). Arranging Exons in different patterns, called 
alternative splicing, enables the cells to make different proteins from a 
single gene (Norvell and Machalek, 2000). Splicing has to be extremely 
accurate; any errors in the splicing process, even one that results in the 
deletion of just one nucleotide in an Exon or the addition of just one 
nucleotide in an Intron, will throw the whole sequence out of alignment. 
The result is usually an abnormal protein or no protein at all (Norvell and 
Machalek, 2000). For example, splicing error mutations are the causative 
factor of one form of Alzheimer's disease (Kinzler and Vogelstein, 1998).  
 
Figure 1.9: Mutation of normal Splicing (Norvell and Machalek, 2000). 
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1.6.4. Repeat Variations Mutation 
 
Genetic variation is important source of genetic material for natural 
selection. The natural selection is the result of the interactions between 
genetic variations in a population and the environment.  A variation 
mutation in the alleles of genes can occur within and among populations, 
which can lead to a permanent change in the primary structure of a gene. 
However there are three primary factors of genetic variation (i) a single 
nucleotide change in the DNA sequence of genes, (ii) A transfer of a gene 
or alleles from one population to another i.e gene flow (gene migration). 
For example, the mixed populations of humans in the USA has proved the 
transfer of malaria resistant gene from the migrant population to the native 
population among whom the gene was absent originally , (iii) introducing a 
new gene combination into a population i.e sex and genetic shuffling. 
(Conrad et al., 2011) 
 
1.6.5. Small Indels Mutation 
The databases used in this study additionally defines a mutation 
class as ‘small indels’ and represent different records from those included 
in the frame shift mutation (see above). ‘Indel’ stands for mutations with 
either an insertion or a deletion, i.e., a mutation class that includes both 
insertions and deletions (Kondrashov and Rogozin, 2004; Ogurtsov et al., 
2004).  Indels differ from point mutations; where an Indel inserts and 
deletes nucleotides from a sequence, a point mutation is a form of 
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substitution that replaces one of the nucleotides (Figure 1.10). Indels can 
also be contrasted with Tandem Base Mutations (TBM), which may result 
from fundamentally different mechanisms (Hill et al., 2003). (See figure 
1.10). 
 
Figure 1.10: Small Indels, where line 1 shows the standard moose sequence, 
with 5th, 6th, & 7th triplets highlighted, Lines 2 & 3 show a single-nucleotide 
insertion (T) or deletion (g) at the sixth triplet, Lines 4 & 5 show a double-
nucleotide insertion (TT) or deletion (gg) at the sixth triplet and Lines 6 & 7 

















1.6.6. Regulatory Mutation 
Cis-regulatory element is a region of DNA or RNA that regulates the 
expression of genes located on that same DNA molecule. The word ‘cis’ 
means “on the same side as” (Wray, 2007).  Regulatory mutations 
represent a significant cause of human disease. According to April 2009 
statistics compiled by the Human Gene Mutation Database, 1459 
regulatory mutations have been identified in over 700 genes that cause 
human-inherited disorders. The majority of these regulatory mutations are 
located in proximal and distal promoter elements (a region of DNA that 
facilitates the transcription of a particular gene) that map within 1 kb of the 
transcript start site (TSS). Cis-regulatory mutations affect a broad range of 




Figure 1.11: Regulatory Mutation: two different promoters are located next to the 
two different genes. By binding to Promoter 1, an enhancer actively regulates 
Gene 1 and leads to its transcription, as indicated by the black arrow above Gene 
1. An insulator prevents this enhancer from activating Gene 2, which is not 









1.6.7. Chromosome Rearrangement Mutations 
1.6.7.1. Translocation  
Chromosomal translocation, a chromosome abnormality or 
aberration caused by rearrangement of parts. The mutation is caused by a 
rearrangement of two different non-homologous chromosomes breaking 
and re-joining, where genes in one part of the one chromosome is 
replaced with another genes in part of different chromosome. A fusion 
gene might be creating as a result of the translocation which knows to be 
a common type for causing cancers (Kinzler and Vogelstein, 1998).  
1.6.7.2. Complex Rearrangements (Inversion) 
This class represents a process where a part of the chromosome is 
reversed end-to-end, and inversions are most likely to happen when 
individual chromosome suffer a break and are then rearranged. There are 
two types of Inversion, the first one can happen in one arm of the 
chromosome which knows to be as ‘Paracentric’ and the other one can 
happened in both of the chromosome arms with the involvement of the 











1.6.7.3. Genetic Duplications/Amplification 
Gene duplication is a mechanism to generate new genetic material 
i.e., molecular evolution. Duplications occurs in chromosomes contains a 
proto-oncogene within them where the number of copies of proto-
oncogene is increased in that chromosome. However these newly 
introduced copies of the proto-oncogene produce protein that is involved 
in stimulating cell growth. Therefore the amount of the produced proteins 
can be increased, which might lead to the cause of cancers (Kinzler and 
Vogelstein, 1998).  
1.6.7.4. Gene Deletion/Deficiencies 
 
Genetic aberration is the process where a part of chromosome or 
DNA sequence is deleted resulting a loss in a genetic material. The 
deletion could be errors in the exchange of genetic material between 
homologous chromosomes (crossing over) during the cell division 












1.7. Literature Review of Gene Mutations in Human 
Cancers 
Various attempts and approaches have been made in order to 
understand genetic mutations classes and the related human cancers 
arising from these mutations. A review of the most cited literature studies 
related to this field is discussed in this section.    
1.7.1. Relationship between Gene Mutations Classes and Human 
Cancer 
During the past decade biomedical researchers have examined a 
small number of cancers sharing commonalities in both etiology and 
pathology. The latest growth in genetics and genomics studies has 
enabled us to interrogate the entire genome for the influence of genes in 
causes of human cancers (Jimenez-Sanchez et al., 2001; Cooper et al., 
2010).  These impressive studies have opened the gates wide for cancer 
genomic research to investigate the implications of mutation classes in 
human cancers.  
Many authors have been able to identify cancers based on mutation 
classes, starting with the Missense/Nonsense mutations, where detection 
of a single nucleotide changes leading the genetic sequence to encode for 
different amino acid. For example in studies of (Sweet et al., 2010; Sluiter 
and van Rensburg, 2011; Bonadona et al., 2011) some cancers (such as 
Breast, Lung and Bowel) were considered as a consequence of altered 
amino acid, that occurred due to dozens of single base-pair substitutions, 
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in a group of genes (e.g., ATM, BRCA1, BRCA2, MSH2, MSH6 and 
MLH1).  
Others have detected how a change of nucleotides during splicing of an 
intron could transform the precursor messenger RNA into mature 
messenger RNA, leading to unusual production of proteins. For example, 
altered distributions of the exonic splicing enhancer motif in ATM gene 
resulted in a change in protein function that are associated to breast 
cancer (Brunet et al., 2008; La Paglia et al., 2010).  
Remaining with the single base-pair substitutions, a regulatory mutation in 
the FAS gene promoter affects gene expression and modulates apoptotic 
signalling and can cause Acute Myeloid Leukaemia (Sibley et al., 2003). 
Yang and co-workers examined 1,840 lung cancer patients and found two 
single nucleotide polymorphisms (SNPs) located in the FEN1 promoter, 
which causes the reduction of FEN1 expression level, leading to the 
development of lung cancer (Yang et al., 2009).  
Small insertions and deletions can alter human genetic sequences and 
can result in cancer formation. One of the most common human genetic 
cancers, breast cancer, is frequently caused by a small coding insertion or 
deletion within the MSH2, MSH6 and MLH1 genes that eliminates a single 
amino acid (Kim et al., 2010; Nilbert et al., 2009). Another form of deletion 
and insertion, include gross deletions for the entire FH gene and gross 
insertions or duplications for the FH gene in two different patients; both 
processes can cause kidney cancer (Bardella et al., 2011; Ahvenainen et 
al., 2008). Others  (Vaughn et al., 2010) have further proposed how the 
whole deletion of the Mismatch repair gene (PMS2) in 22 out 53 patients is 
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principally responsible for a form of bowel cancer (Walsh et al., 2010). 
Discovery of the inheritance patterns for mutations of large 
rearrangements (Gross Insertion) in the BRCA1 gene has revealed the 
importance of this gene in breast cancer. A study of large genomic 
rearrangements (complex rearrangement mutations) in breast cancer 
cases (Engert et al., 2008), has revealed that BRCA1 can harbour cancer-
causing mutations. An analysis of 1,506 German families carrying breast 
and ovarian cancers detected a total of 32 pathogenic rearrangements in 
the BRCA1 genes. BRAC1 gene screening has been carried out on 283 
ovarian cancer patients to detect large genomic alterations, with the 
finding that 12 of these patients exhibit complex rearrangements mutations 
(Ramus et al., 2007). 
A small indel have also been found to be a cancer-causing mutation. It 
tends to have a deletion of a single base or double nucleotide insertions 
affecting the genetic sequence, such as the finding of a small indel 
mutation in HLA-DQA1 causing  lung cancers  (Qiu et al., 1996). Finally, a 
reported study of the MUC6 gene, which is a highly expressed gene in 
stomach and gall bladder, has been carried out on 470 gastric cancer 
patients, which showed that five of these cancer patients are known to 










1.7.2. The Analysis of Genetic Data in Cancer Research 
The past few decades has witnessed a rapid development in 
technologies that can analyze cancer genomes. These have focused on  a 
single platform or type of genetic alteration such as High Resolution Melt 
(HRM) analysis for the detection of novel oncogenes (Nanjundan et al., 
2007). Similarly, the technology of DNA Sequencing (i.e., directed 
sequencing, shotgun sequencing) has been used widely to detect novel 
genes involved in specific cancer types e.g., direct sequencing to detect 
mutations in BRAF causing human cancers (Davies et al., 2002). More 
recently, a combination of genome sequencing and bioinformatics tools 
has been used, e.g., by The Cancer Genome Atlas (TCGA), to catalogue 
genetic mutations associated with cancers. All these developments have 
opened the road widely for new genetic analysis tools. For example, a new 
technique has been implemented to sequence DNA, named as the 
Second-generation sequencing. This new technique offers several 
advantages over previous technologies; (i) allows the whole genome to be 
sequenced, (ii) offers structural information, which has never been 
available before using other platforms, (iii) enables for the first time a 
global assessment of chromosomal rearrangements in cancer. A good 










1.8. Method for the Analysis of Biological Networks 
A network is a graphical representation of relations between 
objects, where these objects potentially interact with each other. In human 
genome research, graphs or networks have been used to represent 
various complex biological processes such as regulatory networks, 
disease networks, and various types of pathway interactions such as 
protein- or gene-interactions. The development of molecular networks was 
begun over 40 years ago using classical molecular tools (Dagley and 
Nicholson, 1970). With the rapid increase genome data, scientists now are 
able to construct more informative molecular networks, such as protein-
protein interaction networks and gene regulatory networks. These 
molecular networks have similarities in terms of their structures. For 
example, the yeast transcription regulatory network (Guelzim et al., 2002), 
the metabolic networks (Wagner and Fell, 2001), and the yeast protein 
interaction network (Wagner, 2001), all have approximately power-law 
degree distribution, where most nodes in the networks interact with one 
other node, and a few can interact with tens or hundreds of others. 
Various mathematical approaches have been used to investigate the 
structure of biological networks including (i) degree distributions of nodes 
(k), (ii) clustering coefficient. The degree distribution (Newman, 2003) is 
used to quantify the properties of each node connecting to other nodes 
within the network. The clustering coefficient is to observe the connections 
of a node and connections made by its neighbours, this observation can 
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only be applied to a large fragment of the network (Newman, 2003). See 
figure 1.12 
 
Figure 1.12: Theoretic illustration of a network (Proulx et al., 2005) (a) divided 
into three components A, B and C outlined with dash line. Each component node 
is represented by circles or squares. These nodes are connected via edges (solid 
black lines). The degree of connectivity for each node varies between 0 and 4, for 
example the central node with degree 4 is shaded darker green. In component 
(A) the shortest path between square node 1 and square node 2 consists of 4 
steps. Whereas component (B) has a high clustering coefficient, due to the 
connectivities of its neighbour (i.e, every set of three nodes is connected within a 
triangle of edges). (b) Comparison of the node degree and frequency 
distributions produced by models of network formation, displayed on a log-log 
plots. Poisson random networks and Power-law degree distributions that appear 









1.9. Aims and Objectives 
The main aim of this study is to investigate the influence of various 
germline mutation classes on different human cancers, by means of (i) 
constructing a Human Cancer Map (HCM) based on a knowledge of 
genes and on their associated mutation classes, (ii) investigating the 
distribution of mutation classes over the newly constructed Human Cancer 
Map (HCM), (iii) constructing a Genome-wide Distribution Map to identify 
the involved genes in the constructed Human Cancers Map, (iv) identifying 
pathways associated with the involved genes in the constructed Genome-
wide Distribution Map, (v) identifying the relatedness of the involved genes 
in the Genome-wide Distribution Map based on their biological roles and, 
(vii)  associating genes with cancer based on the corresponding encoded 
proteins and the protein-protein interactions (PPI) followed by their 
interrogation for Missense/Nonsense mutations.  
This study was conducted in several phases: First, I investigated the 
properties of gene mutation classes in relation to human cancers; second, 
I gathered information about the ten classes of germline mutations 
involved. Third, I prepared the gathered biological data and established 
associations between gene mutations and human cancers. Thereafter, I 
build a human cancer map and a Genome-wide Distribution map based on 
the associations of specific mutation classes. 
The objectives in order to achieve this aim included: 
 Integrating the complementary data sources such as Genome 
database, OMIM, HUGO Gene Nomenclature Committee, Entrez 
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Gene, GeneCards, GenAtlas, GeneClinics, UniGene, SwissPort, 
Human Protein Reference Database, Human Gene Mutation 
Database (HGMD), Genetic Association Database and Sanger 
Database. 
 Designing constructing and analysing networks using various 
bioinformatics tools including R and bioconductor, Cytoscape and 
Gephi network visualization tools. R is a programming language 
that has been widely used for statistical computation, graphics and 
bioinformatics. Cytoscape is an open-source bioinformatics 
software platform for visualizing molecular interaction networks and 
biological pathways and integrating these networks with 
annotations, gene expression profiles and other state data. Gephi 
visualization is a network analysis tool that has been used widely by 
bioinformatics.   
 Designing and constructing a Genome-wide Distribution Map using 
CIRCOS visualizing software package (Krzywinski et al., 2009) and 
Perl Programming Language.  










Chapter Two  
 
2. Material and Methods 
The aims of this chapter are four-fold: (i) to investigate the 
properties of genetics in relation to human cancers, by accessing various 
complementary data sources, including Genome Database (Grzybowska 
et al., 2002), Database of Human Genes and Genetic Disorders (OMIM) 
(Amberger et al., 2009), GeneCards (Safran et al., 2002a), Genetic 
Association Database (GAD) (Becker et al., 2004), Sanger Database 
(Futreal et al., 2004) and the Human Gene Mutation Database (HGMD) 
(Stenson et al., 2009); (ii) to extract genes associated with cancers and 
their associated classes of germline mutations including; Regulatory, 
Complex rearrangements, Gross deletions, Gross Insertions, 
Missense/Nonsense, Repeat Variations, Small deletions, Small indels, 
Small insertions, and Splicing;  (iii) to extract the associated biological 
aspects of these data, with reference to Cancer Research UK and 
PubMed, (iv) to apply the appropriate statistical methods for analysing the 
data. 






2.1. Data Integration 
Data integration can be defined as a process of combining data 
obtained from different sources, with ‘cleaning-up’ the data so as to 
provide a unified view for users. This process is a significant in this study, 
as it involves complex data mining procedures to combine research results 
and findings from different depositories (Halevy, 2001). This process 
results in a new ‘data warehouse’, via procedures of Extracting data from 
various sources, and then Transforming it to construct a database suitable 
for a particular  operation, and Loading it to be in a useable format (ETL) 
for data mining and analytics (Chaudhuri and Dayal, 1997). My aim here is 
to apply the ETL process to perform data extraction from three 
complementary data sources, including Genetic association database 
(GAD), Sanger database (COSMIC) and human gene mutation database 
(HGMD), and then transforming it (e.g cleaning, reformatting, 
standardization, aggregation) into a suitable data set as specific tables 
layout (See figure 2.1). The data described in the next two sections 2.2 
and 2.3 will be manipulated based on the ETL process.  
 
Figure 2.1: Extraction, Transform, and Load (ETL). On the left hand side is the 
list of three main biological databases to be used in this project. The ETL is the 
process to apply for the extracted data, and the data warehouse is when the data 





2.2. Source of Data and Genetic Records Used in this 
Thesis  
 
2.2.1. The Genetic Association Database (GAD)   
The Genetic association Database (GAD) (Becker et al., 2004), is 
an online library archive of published genetic association studies that 
provides a comprehensive, public, web-based repository of molecular, 
clinical and study parameters for more than 130,000 entries of human 
genetic association studies. These includes 19 different disease classes, 
such as cancer, aging, cardiovascular, chemdependency, developmental, 
haematological, immune, infection, metabolic, mitochondrial, neurological, 
normal variation, pharmacogenomics, psychiatric, renal, reproduction, and 
vision. Each entry of the GAD is saved as an independent record and is 
composed of 22 fields (or attributes), including gene symbol, entrez 
GeneID, chromosomal location, associated tag between genes and 
disorders (“Y”, N), DNA position, P-value, reference and its corresponding 
PubMed is and OMIM id, etc.  
The GAD data file was downloaded on 30 November 2011. Out of 21,444 
cancer-related entries, 1,908 were selected based on their positive 
associations with cancers. The selected entries contained 486 unique 








2.2.2. The Cancer Gene Census Database (COSMIC)   
The Cancer Gene Census Database (COSMIC) (Futreal et al., 
2004) is a collection of somatic and germline mutations with classes of 
mutations from  the published literature. The mutation information is based 
on those mutations implicated in the development of particular cancers. 
The COSMIC database stores a total of 1,324 mutations entries. Table 2.1  
summarise the characteristics of COSMIC data. Each entry of COSMIC is 
saved as a unique independent record and is composed of sixteen fields 
(attributes), including gene symbol, name of gene, geneID, chromosome, 
chromosome band, somatic mutation, germline mutation, tumour type 
(somatic mutation), tumour type (germline mutation), cancer syndrome, 
tissue type, cancer molecular genetics, mutation subclasses, 
translocation, other syndromes.  
We downloaded the COSMIC database file on 1st of February 2012. Out of 
487 cancer-related genes, 76 genes were selected with germline 
mutations.  
Table 2.1: Total number of entries for each mutation type, mutation class, gene, 
and chromosome. 
Category Number 
Amplification Mutation 16 
Chromosome location 487 
Frameshift mutation 100 
Germline Mutation 76 
Large deletions 37 
Missense Mutation 141 
Nonsense Mutation 92 
Other mutation 26 
Somatic Mutation 447 
Splicing Mutation 63 
Gene Symbol 487 





2.2.3. The Human Gene Mutation Database (HGMD) 
The Human Gene Mutation Database (HGMD) (Stenson et al., 
2009) is a large depository of broad data on human germline mutations 
with its sub-categories of mutation classes. The mutation data includes 
point mutations of a single base pair with insertions and deletions, 
regulatory and splicing-relevant regions of human nuclear genes, micro-
deletions (indels), repeat variants, gross lesions (deletions, insertions and 
duplications) and complex rearrangements (including inversions, see table 
2.2 for a summary of mutation data). The mutation data was stored as 
independent records and presented on a gene-wise basis, with access to 
the mutation classes data via a hypertext link, including additional data 
sources (i.e., Genome Database (GDB), Online Mendelian inheritance in 
Man (OMIM), HUGO Gene Nomenclature Committee (HGNC), Entrez 
Gene, GeneCards, GeneAtlas, GeneClinics, UniGene, SwissProt and the 
Human Protein Reference Database from each gene page. 
 






In order to extract data from the HGMD Web-based application a 
gene symbol is needed. The gene symbols used here were based on 
merging the GAD and COSMIC gene data, then performing a filtering 
process to remove duplicated genes. In total 520 unique genes were 
selected which represent the cancer-associated genes. The HGMD was 
then extracted manually by entering each of the gene symbols into the 
HGMD Web-based applications. The result of the search included gene 
symbol, gene descriptions, chromosome location, cDNA sequence ID, 
mutation classes, total number of mutations for each gene, total number of 
specific class of mutation for each of the gene, related phenotypes, unique 
mutation ID, PubMed references, and some additional information about 
the gene. I further expanded the search by using cancer names obtained 
from the GAD to increase the chance of finding new cancer-related gene 
and mutation records. As a result a total of 15,264 records were collected, 
with a combination of cancers and some non-cancers disorders for each of 
the 10 different mutation classes. Table 2.3 summarises the total number 
for each manually-curated mutation record. 
Table 2.3: Classes of mutation; with total number of collected records for cancers 
and non-cancer disorders.  
Class of mutation Total number of mutation records 
Missense nonsense 7456 
Small Deletion 3280 
Splicing 1465 
Gross Deletions 1227 
Small Insertions 1111 
Regulatory 280 
Small Indels 177 
Gross Insertions 150 
Complex Rearrangements 82 






For further investigation the entries were cross-checked twice manually to 
ensure there was no duplication of the data and to double-check that the 
collected information is accurate and that none of the records were 
eliminated by the extraction process. As I was only interested in the 
cancer entries, a separation of the data on the basis of cancers and non-
cancers entries was carried out in the data preparation part for each of the 
10 classes. 
2.2.4. DAVID Bioinformatics Database 
Database, Annotation, Visualization and Integrated Discovery 
(DAVID) is an online functional annotation tools program. The tool aims to 
group a list of genes from different organism/species based on measuring 
the agreement of genetic biological functions (annotations). DAVID web-
based tools tend to deliver other services, such as identifying the genetic 
pathways for a given list of genes, using bio-pathways, KEGG pathways 
and more (Sherman et al., 2007). My interest in DAVID online tools is to 
group our genes based on annotation associations using the functional 
classification tools.  
2.2.5. The BioGRID Database 
The Biological General Repository for Interaction Datasets 
(BioGRID) is a public database for genetic and proteomics interactions 
(http://thebiogrid.org/). The BioGRID contains 684,996 physical and 
genetic interaction records, of which 381,026 are about human cells 
(access date:01/10/2012). The BioGRID supplies an important plugin for 





access of interaction data. This plugin was used in this research to search 
for the Physical Protein-Protein interactions related to the 424 selected 
genes (Stark et al., 2011). 
2.3. Data Preparation 
In the original HGMD, the 15,264-curated mutation records have 
much complexity with the data. For example the data was a combination 
of cancers and non-cancer disorder records. Also, many of the cancer 
entries are duplicated using different names/terms or the subtypes of 
cancer disorders are listed together with primary cancer names/categories 
etc. To deal with such data complexity, the non-cancer disorder records 
were eliminated from the list by investigating on a manual basis each of 
the disorders for the 15,264 records and the eliminations informed by the 
published literature studies (e.g., PubMed, OMIM and other online 
libraries) (Amberger et al., 2009). As a result 6,717 non-cancer records 
were eliminated from the 15,264 list (see table 2.4).  
Table 2.4: The total number of eliminations for each of the mutation class for 
cancers and non-cancers disorders. 
Mutation Non-cancer Mutations Cancers 
Mutations 
Missense nonsense 4371 3085 
Small Deletion 1181 2099 
Small Insertions 374 816 
Gross Deletion 325 902 
Splicing 295 1091 
Regulatory 91 189 
Small Indels 34 143 
Gross Insertions 19 131 
Repeat Variations 16 25 
Complex Rearrangements 11 66 






Secondly, the remaining 8,547 cancer records exhibited some 
naming/nomenclature complexity i.e., the primary cancer name had sub-
classification names. For example, Leukaemia has two subclasses - Acute 
Leukaemia and Chronic Leukaemia, and each one of these a variety of 
subtypes. On the other hand many of the cancers were duplicated using 
‘different’ names; e.g., Bowel cancer, Colorectal cancer and Colon cancer. 
These entries with duplicated names should be merged into the cancer 
term “Bowel cancer” etc. To solve this critical issue, a hierarchy list for 
each of the primary cancer names was manually created, followed by 
primary cancer subclass names and sub-subclass cancer names. In other 
words, constructing a family tree for each of the cancers, starting from 
primary, secondary, tertiary and so on. This family tree of cancers 
informed the re-arrangement of the data to be used for further 
development in the project in order to achieve our aims and objectives. 
See table 2.5 for an Illustration of the hierarchy of human cancers, 
constructed based on the terms applied in Cancer Research UK-accepted 
terms (Grzybowska et al., 2002). Moving further and to ensure no more 
complexity of the cancers disorder naming, I cross-checked each of the 
entries using the naming structure of table 2.5. This is to associate each 
cancer with its primary named cancer. While assigning each of the 
individual cancer entries into their ‘primary’ cancer designation (e.g, all 
cancers affecting the bowel designated as ‘Bowel Cancer’ as primary 
name), in some cases several cancers were found to be associated with 
the same mutation. For example,  a Missense/Nonsense mutation in the 





position 389 was found in both Breast and Colorectal cancer (Jensen et 
al., 2010), see table 2.6. Therefore, this mutation record was split into two, 
though both retained the same unique mutation ID. This approach allowed 
me to look at each of the cancer disorders as independent records when 
applying the statistical analysis for each gene mutation and cancer (see 
Tables 2.6 and 2.7). After the required data pre-processing (eliminations, 
merging and splitting) 8,879 mutation records were remained, containing 
424 unique genes and a total of 26 primary unique cancer disorders. Each 
entry was stored as an independent record (see figure 2.2). 
Finally, the data was manipulated to construct a table containing the 
following entries: gene symbol, unique mutation ID, sub class of mutation, 
cancers disorder name, total number of mutations for each gene, total 
number of mutations for each of the 10 different classes of mutations, and 






Figure 2.2: Algorithmic framework for the extractions and preparation of mutations data. The start point at the top of the image shows the two 
extracted databases for finding the cancer-associated genes. Moving to the middle of the image the HGMD database shows the extractions of 
mutation records, while moving down the image shows the split of the data for cancers and non-cancers. This is followed by filtering the data 



























Cancers or None Cancers
Filtering 








Table 2.5: The hierarchy of human cancer disorders (family tree of cancers), 
where the red text represents the primary cancer name, the green text the 
subtype (secondary level) and the black text the tertiary level name. In total there 
are 29 primary cancer names, each one followed by its subtypes. 
 
Hierarchy of cancers  
1 Leukaemia 
1.1 Acute leukaemia 
1.1.1 Acute Myeloid Leukaemia 
1.1.2 Acute Lymphoblastic Leukaemia 
1.2 Chronic leukaemia 
1.2.1 Chronic myeloid leukaemia 
1.2.2 Chronic lymphocytic leukaemia 
1.2.3 Hairy cell leukaemia 





2.1.4 Mixed glioma 
2.2 Astrocytomas 
2.3 Ependymomas 
2.4 Acoustic neuromas 
2.5 Craniopharyngiomas 
2.6 Haemangioblastomas 
2.7 Primary cerebral lymphoma 
2.8 Meningiomas 
2.9 Germ cell tumours 
2.10 Pineal region tumours 
2.11 Pituitary tumours 
2.12 Primitive neuroectodermal tumours (PNETs) 
2.13 Spinal cord tumours 
3 Breast Cancer 
3.1 DCIS- Ductal carcinoma in situ 
3.2 LCIS- Lobular carcinoma in situ 
3.4 Invasive ductal breast cancer 
3.5 Invasive lobular breast cancer 
3.6 Inflammatory breast cancer 
3.7 Paget's disease 
3.8 Rare types of breast cancer 
3.9 Breast Cancer in men 
4 Bowel Cancer 
4.1 Adenocarcinoma 
4.1.1 Colorectal Cancer 
4.1.2 Colon Cancer 
4.2 Squamous cell cancers of bowel 
4.3 Carcinoid tumours 
4.5 Sarcomas of colon 
4.6 Cancers of the lymphatic system in colon 
5 Anal Cancer 
5.1 Epidermoid cancers. 
5.1.1 Large cell keratinising 
5.1.2 Large cell non keratinising (also called transitional) 
5.1.3 Basaloid 
5.2 Non Epidermoid cancer 
5.3 Adenocarcinoma of glandular cells 
5.4 Basal cell carcinoma of anal origin 





5.6 Rectal cancer or cancer of the rectum 
6 Womb Cancer 
6.1 Endometrial cancer 
6.1.1 Endometrioid adenocarcinomas 
6.1.2 Papillary serous carcinomas 
6.1.3 Clear cell carcinoma 
6.2 Adenocarcinoma with squamous cells of womb 
6.3 Sarcoma of the womb 
6.4 Cancer of the neck of the womb (cervix) 
7 Cervical Cancer 
7.1 Squamous cell cancer of cervical 
7.2 Adenocarcinoma of cervical 
8 Ocular cancer or Eye cancer 
8.1 Melanoma of the eye 
8.2 Lymphoma of the eye 
8.3 Rare cancers in children 
9 Gall bladder cancer 
9.1 Adenocarcinoma Gallbladder 
9.2 Squamous cell cancer of the gallbladder 
9.3 Adenosquamous cancer of the gallbladder 
9.4 Small cell cancer of the gallbladder 
9.5 Sarcoma of the gallbladder 
9.6 Neuroendocrine tumour of the gallbladder 
9.7 Lymphoma and melanoma of the gallbladder 
10 Stomach Cancer 
10.1 Adenocarcinoma of the stomach 
10.2 Squamous cell cancers of stomach 
10.3 Lymphoma of the stomach 
10.4 Gastrointestinal stromal tumour (GIST) 
10.5 Neuroendocrine tumours 
11 Kidney cancer 
11.1 Renal cell cancer 
11.1.1 Clear cell 
11.1.2 Papillary (Type 1 and 2) 
11.1.3 Chromophobe 
11.1.4 Oncocytic 
11.1.5 Collecting duct 
11.2 Transitional cell cancer (TCC) of the renal pelvis 
12 Larynx or Laryngeal cancer 
12.1 Squamous cell cancer of larynx 
12.2 Adenocarcinoma of larynx 
12.3 Sarcoma of larynx 
12.4  Myeloma of larynx 
13 Liver cancer 




14 Lung cancer 
14.1 Small cell lung cancer 
14.2 Non small cell lung cancer 
14.2.1 Squamous cell carcinoma of lung 
14.2.2 Adenocarcinoma of lung 
14.2.3 Large cell carcinoma of Lung 
14.3 Mesothelioma 
15 Lymphoma 
15.1 Hodgkin Lymphoma 
15.1.1 Classical types 
15.1.1.1 Nodular sclerosing 
15.1.1.2 Mixed cellularity 
15.1.1.3 Lymphocyte rich 
15.1.1.4 Lymphocyte depleted 
15.1.2 Nodular lymphocyte predominant type 
15.2 Non Hodgkin lymphoma (NHL) 
15.2.1 Cutaneous T cell lymphoma 
15.2.2 Mucosa associated lymphoid tissue (MALT) lymphoma 





16 Melanoma skin cancer 
16.1 Superficial spreading melanoma 
16.2 Nodular melanoma 
16.3 Lentigo maligna melanoma 
16.4 Acral lentiginous melanoma 
16.5 Other types of melanoma 
16.5.1 Internal organs melanoma 
16.5.2  Melanoma of the eye 
17 Mouth and oropharyngeal cancer 
17.1 Mouth and oropharyngeal cells 
17.2 Squamous cell cancers of the mouth and oropharynx 
17.3 Other types of mouth and oropharyngeal cancer 
17.3.1 Salivary gland cancer 




18.1 Light chain myeloma 
18.2 Non secretory myeloma 
19 Oesophageal cancer 
19.1 Squamous cell carcinoma of oesophageal 
19.2 Adenocarcinoma  oesophageal 
19.3 Undifferentiated cancer 
19.4 Rare types of oesophageal cancer 
20 Ovarian cancer 
20.1 Epithelial ovarian cancer 
20.2 Germ cell and other rare ovarian tumours 
21 Pancreatic cancer 
21.1 Exocrine cancers 
21.1.1 Cystic tumours 
21.1.2 Cancer of the acinar cells 
21.1.3 Sarcomas of the pancreas 
21.2 Endocrine pancreatic tumours 
21.3 Lymphoma of the pancreas 
22 Penile (penis) cancer 
22.1 Squamous cell cancer of the penis 
22.2 Adenocarcinoma 
22.3 Melanoma of the penis 
22.4 Basal cell cancer of the penis 
22.5 Sarcoma of the penis 
23 Salivary gland cancer 
23.1 Cells of the salivary gland 
23.2 Benign tumours 
23.3 Mucoepidermoid cancer 
23.4 Acinic cell carcinoma 
23.5 Adenoid cystic cancers 
23.6 Adenocarcinoma 
23.7 Malignant mixed cancers 
23.8 Low grade polymorphous cancers 
23.9 Other types 
23.9.1 Squamous cell carcinoma 
23.9.2 Lymphoepithelioma 
23.9.3 Anaplastic carcinoma 
23.9.4 Poorly differentiated carcinoma 
23.9.5 And other even rarer cancers 
24 Skin cancer (non melanoma) 





24.2 Squamous cell skin cancer 
24.3 Rarer types of non melanoma skin cancer 
24.3.1 Merkel cell carcinoma 
24.3.2 Kaposi’s sarcoma 
24.3.3 T cell lymphoma of the skin 






25.2 Leiomyosarcomas and rhabdomyosarcomas 
25.3 Liposarcomas 
25.4 Synovial sarcomas 
25.5 Angiosarcomas 
25.6 Malignant peripheral nerve sheath tumours 
25.7 Gastrointestinal Stromal Tumours (GISTs) 
25.8 Kaposi's sarcomas 
25.9 Ewings sarcomas and PNETs 
25.10 Fibromatosis 
26 Testicular cancer 
26.1 Seminomas 
26.2 Non seminomas 
27 Thyroid cancer 
27.1 Papillary thyroid cancer 
27.2 Follicular thyroid cancer 
27.3 Medullary thyroid cancer 
27.4 Anaplastic thyroid cancer 
27.5 Rare types of thyroid cancer 
28 Vaginal cancer 
28.1 Squamous cell carcinoma of vaginal 
28.2 Adenocarcinoma of the vagina 
28.2.1 Clear cell adenocarcinoma 
28.2.2 Papillary adenocarcinoma 
28.2.3 Mucinous adenocarcinoma 
28.2.4 Adenosquamous carcinoma 
28.3 Sarcoma of the vagina 
28.4 Melanoma of the vagina 
28.5 Small cell vaginal cancer 
29 Vulval cancer 
29.1 Squamous cell carcinoma of vulval cancer 
29.2 Vulval melanoma 
29.3 Adenocarcinoma 
29.4 Basal cell carcinoma of vulval 
29.5 Verrucous carcinoma of vulval 
29.6 Sarcomas of vulval 
30 Bone cancer 
30.1 Osteosarcoma 
30.2 Ewing’s sarcoma 
20.3 Chondrosarcoma 
30.4 Spindle cell sarcoma 
30.5 Chordoma 
31 Bladder cancer 
31.1 Transitional cell (Urothelial cancer) 
31.2 Non Muscle Invasive 
31.3 Squamous cell bladder cancer 
31.4 Invasive bladder cancer 





The following three tables, 2.6, 2.7 and 2.8 are the example tables related to section 2.3 Data preparation part. 
Table 2.6: Example of two cancers entries based on one Mutation class. 






Mutation Descriptions amino acid changes Ref 
CM103943 MLH1 3p21.3 Breast & 
Colorectal_Cancer 
Missense/Nonsense 875 285 cCGG-TGG Arg389Trp Jensen (2010) Breast Cancer Res Treat 120, 777 
 
 
Table 2.7: Example of Split for the two cancers entries using same Mutation HGMD ID. 






Mutation Descriptions amino acid changes Ref 
CM103943 MLH1 3p21.3 Colorectal_Cancer Missense/Nonsense 875 285 cCGG-TGG Arg389Trp Jensen (2010) Breast Cancer Res Treat 120, 777 






Table 2.8: Example for the filtered data table layout, i.e. an example for one cancer only, “Bladder cancer”, where the phenotype is the cancer 
name, gene is a gene symbols, Mutation classes, total number of mutations for each gene including cancers and non-cancers, total number of 
mutation classes including cancers and non-cancers as well, location of the gene in the chromosome, the collected HGMD unique ID and 
finally a PubMed reference for each mutation and cancer records.  
 












Bladder Cancer ARL6IP5 Regulatory 1 1 3p14 CR057790 Wu (2005) Zhonghua Yi Xue Yi Chuan Xue Za Zhi 22, 64 
Bladder Cancer DDX20 Missense nonsense 1 1 1p21.1-p13.2 CM086198 Yang (2008) Cancer Res 68, 2530 
Bladder Cancer ERCC4 Regulatory 22 1 16p13.3-p13.11 CR102187 Wang (2010) Oncogene 29, 1920 
Bladder Cancer ERCC6 Missense nonsense 74 35 10q11.23 CM0910264 Chang (2009) Anticancer Res 29, 5121 
Bladder Cancer HRAS Missense nonsense 18 13 11p15.5 CM035804 Johne (2003) Cancer Epidemiol Biomarkers Prev 12,68 
Bladder Cancer MDM2 Regulatory 3 3 12q14.3-q15 CR082025 Wang (2008) Clin Cancer Res 14, 3633 
Bladder Cancer OGG1 Regulatory 17 4 3p26.2 CR072322 Figueroa (2007) Hum Genet 121, 233 
Bladder Cancer PTGS2 Regulatory 8 5 1q25.2-q25.3 CR050013 Kang (2005) Cancer Lett 217, 11 
Bladder Cancer TNFRSF10A Regulatory 3 1 8p21 CR117979 Wang (2009) Mutat Res 661, 85 
Bladder Cancer UGT2B7 Missense nonsense 7 2 4q13 CM057512 Lin (2005) Toxicol Sci 85, 502 
Bladder Cancer XPC Missense nonsense 55 21 3p25 CM112197 Qiao (2011) Carcinogenesis 32, 516 
Bladder Cancer XPC Missense nonsense 55 21 3p25 CM112198 Qiao (2011) Carcinogenesis 32, 516 
Bladder Cancer XPC Regulatory 55 2 3p25 CR112196 Qiao (2011) Carcinogenesis 32, 516 
Bladder Cancer XRCC4 Splicing 4 1 5q13-q14 CS075240 Figueroa (2007) Carcinogenesis 28, 1788 
Bladder Cancer XRCC5 Repeat Variations 1 1 2q35 CE075931 Wang (2008) Mutat Res 638, 26 
Bladder Cancer ZNF350 Missense nonsense 1 1 19q13.33 CM074642 Figueroa (2007) Carcinogenesis 28, 1788 
Bladder Cancer MLH1 Small Deletion 875 195 3p21.3 CD105829 van der Post (2010) J Med Genet 47, 464 
Bladder Cancer MSH2 Splicing 860 92 2p22-p21 CS104167 van der Post (2010) J Med Genet 47, 464 
Bladder Cancer MSH2 Gross Deletions 860 190 2p22-p21 CG104168 van der Post (2010) J Med Genet 47, 464 






2.4. Statistical Methods   
 
2.4.1. Cohen’s Kappa (κ) Coefficient 
Cohen’s kappa coefficient was originally proposed by (Carletta, 
1996; Cohen, 1960) to quantify the inter-rater agreement or inter-annotator 
agreement between two individuals. This is thought to be more robust a 
measure than simple percent agreement calculation, since k takes into 
account the agreement occurring by chance. The agreement is calculated 
between two raters, which each classify N items into C mutually exclusive 
categories. The equation for quantifying     
  ( )    ( )
     ( )
  
Where Pr(a) is the relative observed agreement among raters, and Pr(e) is 
the hypothetical probability of chance agreement, using the observed data 
to calculate the probabilities of each observer randomly classifying each 
category randomly. If the raters are in complete agreement then κ = 1. If 
there is no agreement among the raters other than what would be 
expected by chance [as defined by Pr(e)], κ = 0.  
However Kappa’s strength lies in its ability to take into account chance 
agreement between two or more observers. A second strength of Kappa 
lies in its known sampling distribution. Kappa’s weakness is that it takes 








Weighted Kappa Statistic 
The weighted kappa coefficient is a generalization of the simple kappa 
coefficient, using weights to quantify the relative difference between 
categories. The weighted kappa is useful in programming, when codes are 
sequential in order (Cohen, 1968).  
The equation for weighted      
∑    ∑           
 
 
∑     ∑   
 
       
 
Where k = number of codes and   ,     , and     are elements in the 
weight, observed, and expected matrices, respectively. When diagonal 
cells contain weights of 0 and all off-diagonal cells weights of 1, this 
formula produces the same value of Kappa as the calculation given above. 
Interclass Correlation Class (ICC) 
The interclass correlation coefficient is useful for measuring the 
degree of dependence of observations within a group (Koch, 1983) to 
determine how similar are the values of some variables within the same 
group. Essentially, it is a measure of the within subject (group) variability. 
Within each group, the mean of a value can be computed, and if values 
are similar then the difference between the mean and a single value will 
be small. The ICC is particularly relevant for work with families and 








The hypothesis of the current project is to quantify the degree (κ) of 
agreement between two or more connected cancers on the basis of the 
shared genes. In this study, I distinguished the association degree if two 
cancer into four classes: “very connected”, “highly connected”, and 
moderate connected” and “low connected”. Two cancers are defined as 
very connected if k = (0.75 to 1), highly connected if k = (0.5 to 0.75), 
Moderate connected if k = (0.25 to 0.5) or with low connectivity of k = 
(<0.25).  
Theoretical example  
 
Table 2.9: Theoretical example table. Set of five genes and four cancer types. If a 
gene and cancer are related the number 1 will be added to the table and if they 






Table 2.10:  This 3 x 3 table, based on table 2.9 above, shows the scoring of 
cancer entries where ‘1’ represents a positive gene association and 0 represents 








 Gene1 Gene 2 Gene 3 Gene 4 Gene n 
Cancer A 1 1 1 0 0 
Cancer B 1 1 1 1 0 
Cancer C 0 0 1 0 1 
Cancer D 1 0 1 0 1 





  1 0 
1 3 
(    ) 
1 
(    ) 
4 
(    ) 
0  0 
(    ) 
1 
(    ) 
1 
(    ) 
Column total  3 
(    ) 
 2 
(    ) 
 5 





Three steps are needed to derive the value of k; 
1. Calculate the observed percentage agreement,     
          
    
 = 
   
 
     
2. Calculate the probability of random agreement 
     
                    
       
  
       
   
      
3.  Calculate the degree of k,     
       
      
  
         
      
       
 
2.4.2. Density 
In this study, I am interested in investigating the density of cancer-
associated genes in each chromosome as this may provide some 
measure structural insight. The method of mass density (density) is a 
measure of mass contained per unit volume. Mathematically, density is a 
mass divided by volume   
 
 
 , where   signify density,   signify mass, 
and   signify volume (S Dole, 2009). Here, the density formula that is 
going to be used to calculates the density of the collected cancer genes in 
each chromosome, where  the number of cancer genes is assigned to a 
particular chromosome and   is the total number of the identified genes on 








The 3 complementary data sources, (i) Genetic Association 
database (GAD) (Becker et al., 2004), (ii) The Cancer Gene Census 
Database (COSMIC) (Futreal et al., 2004), (iii) Human Gene Mutation 
Database (HGMD) (Stenson et al., 2009), were successfully extracted and 
integrated in this study. In the GAD a total of 1,908 cancer-related entries 
was selected and 1,324 entries selected from COSMIC. Filtering these 
extracted 3,232 cancer-related gene records from both databases resulted 
in a list of 520 genes. Based on these filtered 520 genes, a subsequent 
manual extraction of 15,264-germline mutation class records were 
obtained including; Missense nonsense, Splicing, Regulatory, Small 
deletions, Small Insertions, Small Indels. Gross deletions, Gross 
Insertions, Complex rearrangements and Repeat variations, from the 
HGMD, for cancer and non-cancer disorders.  
The newly constructed database was achieved by performing a splitting 
process to clarify two groups of mutation records; the first consisted of a 
total of 8,547 cancer mutation records and the second 6,717 non-cancer 
mutation records. The clarified 8,547-cancer mutation records, was 
successfully screened further by introducing a ‘hierarchy’ to cancer 
disorder names (family tree of cancers) using the Cancer Research UK 
and PubMed literature. The introduced hierarchy consisted of 31 primary 
cancer name terms and 206 secondary and tertiary cancer names. The 
newly screened data was stored in a table as an independent record for 
each gene symbol. Each record consisted of Primary cancer name, Gene 





total number of evident mutations for each gene including cancers and 
non-cancers mutations, the total number of mutations for each of the 
implicated class, gene chromosome location and PubMed literature 
reference. In total I achieved 8,879 Mutations records including 424 
unique genes and 29 primary cancer disorder names.  
The method Choen’s Kappa Coefficient was used to measure the 
agreements between two cancers in order to determine if there can be 
connected nodes in the to-be constructed Human cancer map.  
These achieved our objectives in relation to the biological data and 
detected mathematical methods were then used in the next two chapters 
to extract some biological meaning in order to increase our understanding 
of how mutation can impact on cancer development. 
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Chapter Three  
 
3. Association of Human Cancers, Genes and 
Mutations Classes 
Cancers can develop in response to multiple contributory factors 
and can be associated through various factors (principally genetic ones). 
Many authors have shown the value of revealing cancer associations 
based on cancer-causing genes (Goh et al., 2007; Barabási et al., 2011). 
Others have assessed cancer development based on an analysis of gene 
expression to identify the proteins that may act on similar disease-causing 
pathway(s) (Dreze et al., 2010; Goehler et al., 2004). The aim of the work 
presented in this chapter is to investigate the associations of cancers 
based on the involvement or usage of particular genetic mutation classes. 
Using this approach, I intend to explore whether genetic mutation classes 
vary from one to another in terms of their associations to cancers. The 
curated mutation data shows that the association of various cancers 
correspond to gene mutation(s) very differently. For example, Breast 
cancer is associated to ten different types of mutations in each of several 
genes, while Bone cancer is associated to just two different types of 
 
CHAPTER THREE 




mutation based on the same causing gene. In order to gain greater insight 
into the nature of the associations between cancers, and the association 
of gene mutation type and the target cancers, I conducted a series of 
investigations, including: (i) constructing and analysing a Human Cancers 
Map (HCM) based on genetic mutations in human genome, (ii) 
investigation into the distribution of mutations classes over the HCM (iii) 
constructing a Genome-wide Distribution Map to identify the involved 
genes in the HCM   (IV) identifying pathways for the involved target genes, 
(V) to cluster genes based on the relatedness of their  biological factors. 
 
3.1. A Human Cancer Map Based on Genes and Their 
Associated Mutation Classes 
The map connecting human cancers for investigating the association 
between cancer disorders was manipulated by running a string (loop 
statement) in R, to loop the 8,879 curated mutation records based on table 
2.8 (see chapter 2). Two cancer disorders are connected if they involve a 
common gene due to same mutation class and not only with associated 
gene itself (Figure 3.1). 
The Human Cancer Map (HCM) displayed many connections between 
cancer nodes, with each of these connections corresponding to an 
implicated gene and a contributing mutation class. Of 26 primary cancers, 
20 had at least one link to other cancers in the HCM. Sixty-nine genes 
(from total gene set of 424) underpinned these links between cancers. 
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This suggests that the genetic origin and associated mutation class plays 
a central role in associations between cancer nodes.  
 
Next, the degree of connectivity (k) of nodes distributed in the HCM was 
assessed. Seven cancers, representing one particular hub in the HCM, 
were found to be connected to a large number of other cancers as 
indicated by their high k value. For example, Bowel cancer (k = 18), Lung 
cancer (k =17), Breast cancer (k = 16), Brain tumours (k = 13), Ovarian 
cancer (k =13), Stomach cancers (k = 12), and Melanoma (k = 11). This 
finding indicates that each of these cancers is associated with several 


















Figure 3.1: Human Cancer Map (HCM). Each node corresponds to a primary 
cancer and a link between two nodes represents the presence of shared cancer 
genes and mutation class. 
Key to Figures 3.1 to 3.12. The size of each node is proportional to the number of 
interconnections shared by that node i.e., number of distinct primary cancers 
connecting to it. The colours assigned to the node represent the number of 
interconnected links between primary cancer types, and the width of the link-lines 








3.1.1. Investigations into the Distribution of Mutation Classes in a 
Constructed Human Cancer Map 
The distribution of mutation classes behind the Human Cancer Map 
(HCM) was next investigated, to gain a clearer understanding of the 
impact of the underlying mutation class to various cancers.  This 
investigation was based on extracting a mutation-based classes-HCM 
(CM-HCM) from the main HCM (Figure 3.1), with each map corresponding 
to a specific mutation type (see figures 3.2~3.11) and the corresponding 
tables (A1.1~A1.10). 
 
The ratio for the distribution of each mutation class was calculated based 
on the total number of the interconnections (links) between cancers nodes 
for each of the CM-HCMs divided by the total number of interconnections 
for the whole HCM. In total there are 171 interconnections in the HCM. Of 
these 44% were for Missense/Nonsense; 14% small deletion, 9% splicing, 
10% regulatory, 10% small insertion, 6% gross deletion, 3% small indels, 
1% gross insertion, 1% complex rearrangement and finally 2% repeat 
variation (Figure 3.12).  
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Figure 3.2: Missense/Nonsense CM-HCM. Each node corresponds to a primary 
cancer with a total of 19 notes and 76 links. The size of the node is proportional 
to the number of links. Two cancer nodes are connected if there is at least one 
identical gene implicated in both nodes.  The width of the links (connections) is 
proportional to the number of genes implicated in both cancer nodes. For a full 
















Figure 3.3: Small deletion CM-HCM. Each node corresponds to a primary cancer, 
totalling 12 nodes with 24 links. Full lists of cancer nodes and associated genes 
please see Appendix 1 table A1.2. 
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Figure 3.4: Splicing CM-HCM. Each node corresponds to a primary cancer in 
which there are a total of 12 nodes with 16 links. For full lists of cancer nodes and 
associated genes please see Appendix 1 table A1.3. 
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Figure 3.5: Small Insertions CM-HCM. Each node corresponds to a primary 
cancer and a total of 11 nodes with were detected for this SM-HCM. 18 links For 









Figure 3.6: Regulatory CM-HCM. Each node corresponds to a primary cancer, 
with a total of 11 nodes with; 17 links for the regulatory SM-HCM network. For a 
full list of cancer nodes and associated genes please see Appendix 1 table A1.5.  
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Figure 3.7: Gross deletion CM-HCM. Each node corresponds to a primary 
cancer, with 8 nodes and a total of 10 links for this SM-HCM. For a full list of 
cancer nodes and associated genes please see Appendix 1 table A1.6. 
 
 
Figure 3.8: Small Indels CM-HCM. Each node corresponds to a primary cancer, 
with a total of 8 nodes with, 5 links for this small indels network. For a full list of 
cancer nodes and associated genes please see Appendix 1 table A1.7. 
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Figure 3.9: Repeat Variation CM-HCM. Each node corresponds to a primary 
cancer with a total of 3 nodes and 3 links for this, gross deletion network. For a 






Figure 3.10: Complex Rearrangement HCM. Each node corresponds to a primary 
cancer in which there is a total of 2 nodes with a single link. See Appendix 1 table 









Figure 3.11: Gross Insertion HCM. Each node corresponds to a primary cancer, 
with a total of 2 nodes with a single link. For a full list of cancer nodes and 




Figure 3.12: Distribution of mutation classes. The pie chart shows the % 
































3.1.2. The Extent of Agreement between Cancers interconnected 
Nodes Classes Mutation- Human Cancer Map. 
The method of Choen’s Kappa was applied to quantify the 
agreement between two connected cancer nodes in the CM-HCMs. The 
agreement revealed a number of interesting relationships between cancer 
nodes across the SM-HCMs (Figure 3.13): (1) Missense/Nonsense 
mutations, which formed 44% of the CM-HCM and regulatory mutation that 
formed 10% of the CM-HCM both showed low to moderate agreements 
between their connected nodes; (2) Small deletions, splicing, small 
insertions, gross deletions and small indels, which formed between 3% to 
14% of the CM-HCM exhibited low to very high agreements. (3) Repeat 
variation, complex rearrangement and cross insertion mutations, which 
formed only 1% to 2% of the CM-HCM showed very low agreements 
between their interconnected cancer nodes, Refer to appendix 1 tables 
(A1.1, A1.2, A1.3, A1.4, A1.5, A1.6, A1.7, A1.8, A1.9 and A1.10) for the 
full cancer node agreements details. 
 
Subsequently, two of the connected cancer nodes i.e., breast and ovarian 
cancers, appeared to be highly agreed for splicing, small insertions and 
small indels mutations for the following six genes (BRCA1, BRCA2, 
BRIP1, RAD51C, RAD51D, TP53). This finding confirms the results of 
several previous studies (Welcsh and King, 2001; Grzybowska et al., 
2002), showing that germline mutations predisposes to breast and ovarian 
cancer in the BRCA2 and BRCA1 genes. Similarly, the current study found 
that brain tumours tend to be highly linked to melanoma, womb and bowel 
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cancer in terms of their associated splicing, small insertion, gross deletion 
and small indels mutations for three genes (MLH1, CDKN2A and BRAC2). 
On the other hand, it was evident that melanoma and pancreatic cancer 
nodes were highly agreed in terms of their associated splicing and small 
insertion mutations for two genes (CDKN2A, BRAC2). This is supported by 
several scientific reports (Whelan et al., 1995; Goldstein, 2004; de Snoo et 
al., 2008) showing strong associations between pancreatic and 
melanoma. The current study also revealed that melanoma exhibited very 
high agreement with the head and neck cancer at the small indels 
mutations by the CDKN2A gene, which have been shown by (Cabanillas 
et al., 2011) in their  study of a novel germline mutation in the CDKN2A 
gene in head and neck squamous cell carcinomas and melanoma. The 
gene CDKN2A is therefore an active gene as its mutations tends affact 
many cancers. Similarly, prostate cancers agreed too many other cancers 
such as melanoma, pancreatic cancer and lung cancer in terms of their 









Figure 3.13: Agreement Distributions in CM-HCM. Blue shows low agreements (<0.25), purple represents moderate agreements 
((0.25 to 0.50), green reflects all high agreement (0.50 to 0.75), while red refers to the very high agreement (0.75 – 1). The 
mutations subclasses names are placed under each bar. 
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3.2. A Genome-Wide Distribution Map for Cancer Genes 
A Genome-wide Distribution Map for Cancer Genes was 
constructed, based on the data described in table 2.8 of chapter 2, in order 
to explore the association between the identified 424 cancer genes and 
the 26 primary cancers mutation class and distributions as well as their 
positions in the human genome. In order to probe the genome for these 
424 genes the start and end position of the corresponding genes in the 
human genome are needed. One of the most comprehensive genetic 
sequence databases, i.e. GeneCards, (Rebhan et al., 1997; Safran et al., 
2002b) was used to extract the start and end position of each gene in 
genome. The Genome-wide Map was constructed using CIRCOS 
visualizing software package, which was used to construct a distribution of 
Genome-wide mutations in humans (Figure 3.14).   
Subsequently, the density is mass divided by volume    
 
 
, where   
signify density,  signify mass, and   signify volume. Here the density of 
the explored genes was calculated for each chromosome as well as the 
distributions of the ten mutation classes explored in this study (see figure 
3.15).  
The following interesting characteristics were revealed: (1) Chromosome 
17 is a highly represented chromosome for cancer-associated genes, 
whereas chromosome X is the lowest chromosome for adopting cancer-
associated genes, (2) Chromosomes 2,3,7,10,17 and 22 all contained 
genes represented in all the 10 different mutation classes, (3) Missense 
nonsense mutations were a highly spread mutation class over the entire 
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human genome, whereas the complex rearrangement mutation class 
exhibited the lowest spread of mutations over the human genome (see 
figure 3.15). Please note, these observations apply only to the 424 gene 
set used here that relates to 26 primary cancers (includes the top 10 most 
common cancers to affect humans worldwide) and 10 mutation classes.  
However, these data cannot be used to infer relevance to other cancers 
and other disorders. For statically significance evaluation, subsequent 
studies will need to interrogate clinical data and include more genes, 
cancers and mutation recorders to gain a fully comprehensive view of the 
impact of both mutation class and individual chromosome involvement. 









Figure 3.14: Genome-wide Distribution map for cancer genes. Blocks in the outer 
circle, to which are attached the 424 cancer genes, reflect chromosomes. 
Between chromosomes blocks and chromosome number are black bars 
representing the total number of mutations for each gene. The inner circle 
contains the abbreviations for cancers names for each chromosome. For full 
details of genes, cancers and mutations see table A.2.1 Appendix 2. 
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Figure 3.15: Distributions of genes and genetic mutations over all human chromosomes. Here the bars represent cancer mutations in each of 
the 23 chromosomes. The component colours of the blocks on these bars reflect a different subclass of mutations. The blue line across the 















































3.2.1. Identification of Genes Involved in a Human Cancer Map, 
Using their Genome-Wide Distribution  
Identification of genes involved in the Human Cancer Map (Figure 
3.1) was performed based on the gathered underlying gene records and 
the mutation classes records involved in driving the connections between 
cancer nodes in the HCM. In this way 69 genes were discovered from 
4,964 mutation records, which are involved in 20 primary cancers. Based 
on these 4,964 mutation recorders, a string in R was run to associate 
genes to each other. Two or more genes were associated if they are both 
involved with the same cancer via the same mutation class. For example 
the genes XPC, ERCC6 are considered to be associated each other 
because both tended to be causative genes for Bladder cancer at the 
same Missense/Nonsense mutation. Meanwhile the gene MLH1, will be 
excluded from an association for this particular cancer because it is 
associated by a different type of mutation class (i.e., small deletions), 
whereas Bowel cancer can associated the three genes (XPC, ERCC6 and 
MLH1) based on missense nonsense mutation. As a result a total of 1,158 
associations/connections between the 69 cancer genes were extracted. 
These were further explored in CIRCOS to construct a genome-wide 
distribution map of human cancer, and so present the 1,158 associations 










Figure 3.16: Genome-wide mutations, where the blocks in the outer circle reflect 
particular chromosomes and 69 genes attached to each chromosomes position. 
The inner interconnections represent associations between two or more genes 
connected if they contribute to same cancer and the same mutation class. The 









3.2.2. Investigations on the Distribution of Chromosomes, Mutation 
Classes and Genes in a Genome-Wide Distribution Map 
The investigation of the distribution of chromosomes, mutation 
classes and genes in the constructed genome-wide distributions (Figure 
3.16) was done by extracting data of Figure 3.16 into eight genome-wide 
distribution figures, each of which represents a mutation subclass with 
interconnections of the genes cross the human genome (Figures 3.17 to 
3.24). Thereafter the distributions of the 69 associated genes in each 
chromosome were calculated (Figure 3.25) to show the number of 
implicated genes on each chromosome.  Ch17, Ch1, Ch15, Ch2 and Ch3 
tended to contribute to cancer genes disproportionally compared with 
others, whereas Ch22 and Chy did not show any contribution to any of the 
cancer –associated genes.  
As outlined in eight sub-genome-wide mutation diagrams (figures 3.17 to 
3.24), it was clear that Missense/Nonsense mutations has the highest 
impact to human cancer as contributing broadly across the human 
chromosomes, as well in the interconnections between genes. This 
indicates that Missense/Nonsense mutations could be ‘driver mutation’ in 
these interconnecting genes, followed by other mutation classes (i.e., 
regulatory, small deletions, splicing, gross deletions, small insertions, 
small indels and repeated variations). Surprisingly gross insertion and 
complex rearrangement mutations had no impact on the interconnecting 
genes.    
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Figure 3.17: Missense/Nonsense distribution of Genome-wide mutations, where 
the blocks in the outer circle reflect the chromosomes with the 54 genes attached 
to their corresponding chromosomes. The inner interconnections represent 
associations between two or more genes connected if they contribute to same 











Figure 3.18: Small deletion distribution of Genome-wide mutations, where the 
blocks in the outer circle reflect the chromosomes, with 14 genes attached to 
their corresponding chromosomes. The inner interconnections represent 
associations between two or more genes connected if they contribute to same 










Figure 3.19: Splicing distribution of Genome-wide mutations, where the blocks in 
the outer circle reflect the chromosomes, with the 12 genes attached to their 
corresponding chromosome the inner interconnections represent associations 
between two or more genes connected if they contribute to same cancer.  The 
colours of the interconnections represent the corresponding chromosome.  
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Figure 3.20: Small Insertions distribution of Genome-wide mutations, where the 
blocks in the outer circle reflect the chromosomes, with 9 genes attached to their 
corresponding chromosome positions. The inner interconnections representing 
associations between two or more genes connected if they contribute to same 
cancer. The colours of the interconnections represent the colours of the 
corresponding chromosome.  
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Figure 3.21: Regulatory mutation distribution of Genome-wide mutations, where 
the blocks in the outer circle reflect the chromosomes, with 14 genes attached to 
their corresponding chromosomes. The inner interconnections represent 
associations between two or more genes connected if they contribute to same 
cancer. The colours of the interconnections represent the colours of the 
corresponding chromosome.  
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Figure 3.22: Gross Deletion distribution of Genome-wide mutations, where the 
blocks in the outer circle reflect the chromosomes, with the 7 genes attached to 
their corresponding chromosomes. The inner interconnections represent 
associations between two or more genes connected if they contribute to same 









Figure 3.23: Small Indels distribution of Genome-wide mutations, where the 
blocks in the outer circle reflect the chromosomes, with 4 genes attached to their 
corresponding chromosomes. The inner interconnections represent associations 
between two or more genes connected if they contribute to same cancer. The 









Figure 3.24: Repeated Variation distribution of Genome-wide mutations, where 
the blocks in the outer circle reflect the chromosomes, with the 2 genes attached 
to their corresponding chromosome. The inner interconnections representing 
associations between two or more genes connected if they contribute to same 









Figure 3.25: Distribution of the 69 involved genes in the Ggenome-wide 
distributions map for cancer genes over all human chromosomes. 
 
3.2.3. KEGG pathways for the 69 linked Genes Identified in Genome-
Wide Distribution sub-MAPs for each Mutation Class 
The Kyoto Encyclopedia of Genes and Genome (KEGG) pathway 
database (Kanehisa et al., 2006) was used to identify the pathways 
represented in the Genome-wide Distributions sub-maps for each mutation 
class (Figures 3.17 to 3.24). This was carried by entering individual gene 
subsets of each Genome-wide Distribution sub-map (i.e. 10 mutation 
classes) into the pathway database.  
The results showed that 66% of the missense nonsense and 71% of 
regulatory Genome-wide Distribution Map genes were mapped into 
pathways (Figure 3.26) and (Table 3.1), whereas other genome wide 
distribution genes showed no tendency to be in any pathways, and so the 




























These findings indicate that missense nonsense and the regulatory 
mutation genes are involved in eight relevant pathways (1) Pathways in 
cancer, (2) Colorectal cancer, (3) Endometrial cancer, (4) Bladder cancer, 
(5) Mismatch repair, (6) P53 signalling pathways, (7) Cell cycle, and (8) 
Prostate cancer. Correspondingly, the missense nonsense and regulatory 
mutations showed for six identical cancers (1) Bladder cancer, (2) Bowel 
cancer, (3) Breast cancer, (4) Lung cancer, (5) Ovarian cancer, and (6) 
Prostate cancers in the constructed Genome-wide Distributions diagrams. 
This is an indication that these two classes of mutations could be the 
driver mutations in their interconnected genes to cause cancer (see table 










Figure 3.26: Pathways (KEGG) for Missense/Nonsense and regulatory mutations. The bar represents the percentage of genes involved in each 
pathway. The red is regulatory mutations and the yellow is a Missense/Nonsense mutation gene. 
 
CHAPTER THREE 




Table 3.1: Identified pathways for Missense/Nonsense and Regulatory mutation classes. For the involved genes in the construction of the 
Genome-wide Distribution Maps, The 1st column represents the identified pathway names (from KEGG). The 2nd column is the number of 
genes involved on the particular pathway for Missense/Nonsense mutation. The 3rd column is the number of genes involved in the particular 
pathway for regulatory mutation. The 4th column shows the gene symbols for the involved genes in the particular pathway for missense 
mutation. The 5th column shows the gene symbols for the involved genes in the particular pathway for regulatory mutation. The ‘0’ means no 
genes were involved in that pathway, while ‘NA’ mean no available genes are reported for this KEGG pathway. 
Pathway Term 
Number of genes 
involved in a pathway 
(Missense/Nonsense) 
Number of genes 
involved in a 
pathway 
(Regulatory) 
Missense/Nonsense involved genes 
 
 
Regulatory involved genes  
 
 
Pathways in cancer 16 9 
BMP4, EGFR, MSH6, AR, PTGS2, MSH2, VHL, 
ERBB2, MET, TP53, PML, MLH1, BRCA2, CDH1, 
CDKN2A, AXIN2 
PTGS2, KLK3, MSH2, BCL2, TP53, 
MLH1, MDM2, BRCA2, MYC 
Coloursectal cancer 7 5 EGFR, MSH6, MSH2, MET, TP53, MLH1, AXIN2 MSH2, BCL2, TP53, MLH1, MYC 
Endometrial cancer 6 3 EGFR, ERBB2, TP53, MLH1, CDH1, AXIN2 TP53, MLH1, MYC 
Bladder cancer 5 3 EGFR, CDKN2A, ERBB2, TP53, CDH1 TP53, MDM2, MYC 
Mismatch repair 4 2 MSH6, MSH2, MLH1, MLH3 MSH2, MLH1 
Homologous recombination 4 0 RAD51C, MRE11A, BRCA2, RAD50 NA 
Melanoma 5 0 EGFR, CDKN2A, MET, TP53, CDH1 NA 
Pancreatic cancer 5 0 EGFR, CDKN2A, ERBB2, TP53, BRCA2 NA 
Non-homologous end-joining 3 0 XRCC4, MRE11A, RAD50 NA 
Non-small cell lung cancer 4 0 EGFR, CDKN2A, ERBB2, TP53 NA 
p53 signalling pathway 4 3 CDKN2A, TP53, CHEK2, ATM TP53, MDM2, CHEK2 
Cell cycle 5 4 CDKN2A, TP53, BUB1B, CHEK2, ATM TP53, MDM2, CHEK2, MYC 
Renal cell carcinoma 4 0 VHL, MET, FLCN, PTPN11 NA 
Adherens junction 4 0 EGFR, ERBB2, MET, CDH1 NA 
Base excision repair 3 0 XRCC1, PARP1, OGG1 NA 
Prostate cancer 4 4 EGFR, AR, ERBB2, TP53 KLK3, BCL2, TP53, MDM2 
Nucleotide excision repair 3 0 ERCC6, XPC, ERCC2 NA 
Steroid hormone biosynthesis 3 0 CYP1B1, CYP1A1, CYP19A1 NA 
Basal cell carcinoma 3 0 BMP4, TP53, AXIN2 NA 
Glioma 3 0 EGFR, CDKN2A, TP53 NA 
Small cell lung cancer 0 4 NA PTGS2, BCL2, TP53, MYC 
Chronic myeloid leukaemia 0 3 NA TP53, MDM2, MYC 








3.2.4. Functional Analytics of the Clustered Genes Groups  
The 69 linked genes in the Genome-wide Distribution Map were 
clustered into three gene groups, based on the similarities of their shared 
biological functions (within DAVID; (Da Wei Huang and Lempicki, 2008). 
This generated gene-to-gene annotations, and outputted the result into a 
group of functionally-related genes. Using the kappa statistics method, 
only kappa agreement ≥0.35 is considered to reach the required threshold 
for biological function similarity.  
 
Results from these analyses indicated:  
(1) Clustered genes in Group 1 (i.e., RAD50, MRE11A, NBN, 
MLH3, MSH6 and MLH1) show high interconnectivity as they are a) 
functionally-related genes (by DAVID), b) are shared by four cancers (i.e., 
Bowel, Breast, Ovarian and Womb by my Genome-wide Distribution Map), 
c) appear in the sub-maps of each of three mutation classes (i.e., 
missense/nonsense, small deletion and small indel mutations). In this way 
these genes are not just functionally-related but may also be cancer-
related (see figure 3.27).  
(2) Clustered Group 2 genes (i.e., ERBB2, EGFR, MET and 
ERBB4) while a) functionally-related (Via DAVID), b) less interconnected 
in terms of cancer-relatedness within my Genome-wide Distribution sub-
maps, and c) only 2 genes (i.e. EGFR and ERBB2) were found to be 
cancer-related by sharing the same Missense/Nonsense mutation by 
Breast and Lung cancer (see figure 3.28),  
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(3) The clustered Group 3 genes (i.e., CYP11A1, CYP19A1, 
CYP1A1, CYP1B1) are a) functionally-related (via DAVID), b) three of 
these 4 genes (i.e. CYP19A1, CYP1A1, CYP1B1) show good 
interconnectivity in my Genome-wide Distribution sub-map, and c) were 
found to be cancer-related by sharing the same Missense/Nonsense 








         
Figure 3.27: Functional clustering Group 1: Grey circles represent genes; black arrows connecting these genes on the bases of similarity 
threshold (i.e.     ), for shared biological function; coloured arrows leaving each gene (black circles) and entering an oval (mutations) show 









Figure 3.28: Functional clustering Group 2: Grey circles represent genes; black 
arrows connecting these genes on the bases of similarity threshold (i.e.     ), 
for shared biological function; coloured arrows leaving each gene (black circles) 
and entering an oval (mutations) show the mutation class affecting that particular 
gene; arrows leaving an oval to enter a square show the cancer type associated 










Figure 3.29: Functional clustering Group 3: Grey circles represent genes; black 
arrows connecting these genes on the bases of similarity threshold (i.e.     ), 
for shared biological function; coloured arrows leaving each gene (black circles) 
and entering an oval (mutations) show the mutation class affecting that particular 
gene; arrows leaving an oval to enter a square show the cancer type associated 














This chapter performed 
(i) investigation into the influence of gene mutation classes, as a 
major biological factor in human cancers,  
(ii) development of a human cancer map (HCM) based on genetic 
mutation classes data, and investigate the level of agreement 
(kappa) between interconnected cancer nodes 
(iii) construction of a Genome-wide Distribution Map for cancer 
genes to identify KEGG pathways and thereafter to cluster 
genes into functionally-related groups based on their biological 
function.  
Based on HCM, I explored the interconnectivity between cancer nodes in 
HCM sub-maps and noted some interesting features: 
1. Bowel, Lung, Breast cancers presented as 3 central hubs that all 
connected to many other cancers (incl. melanoma, ovarian, 
stomach, prostate and brain cancers). Therefore, these three 
primary cancers represent major connecting cancer types in the 
HCM and may reflect the dominant position in these disorders in 
the human cancers. This is reflected by their position in the top 3 of 
most common cancers with a combined total lifetime risk of 1:15 as 










2. The Missense/Nonsense class of mutations dominated the HCM, 
comprising a full 44% of all HCM interactions. By contrast, the 
remaining 9 mutation classes accounted for only 1%-14% of the 
HCM. However, while a Missense/Nonsense mutation appears to 
represent the most common cancer-inducing form of mutations, the 
kappa value for their interconnectivity was generally low.    
3. By contrast, 5 other mutation classes (i.e., small deletions, splicing, 
small insertions, gross deletions and small indels) exhibited high 
kappa values (i.e., level of agreement) between connected nodes. 
This suggests that mutations of these types could be an important 
focus for future investigation into both the nature of cancer 
etiologies and associated potential therapeutic interventions.  
4. The highest kappa values were found for 8 genes (i.e., BRCA1, 
BRCA2, BRIP1, RAD51C, RAD51D, TP53, MLH1, and CDKN2A), 
suggesting that these genes are particularly important connecting 
genes for 10 of the 29 (i.e., 34%) primary cancer nodes in HCM. 
 
Based on Genome Wide Distribution Map,I explored the nature of the 
interconnected 69 cancer genes sub-maps (derived from the full 424 gene 
set), and found some interesting features: 
1. Chromosome 17 carried the highest number of cancer-related 
genes (14% of total), with chromosome X carrying the fewest (1%).  
2. Chromosomes 2,3,7,10,17 and 22 exhibited cancer-related gene 
mutations all the 10 classes.   
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3. The Missense/Nonsense Mutation type was the most common of 
all mutation classes, and was detected in all 22 chromosomes. 
Moreover, a mutation of the Regulatory Mutation type was 
detected in 11 of 22 chromosomes. Together these mutation types 
were most commonly associated with cancer-pathway genes.  
4. By contrast, mutations of the Gross Insertion and Complex 
Rearrangement classes were not associated with cancer. 
5. Six genes (i.e., RAD50, MRE11A, NBN, MLH3, MSH6 and MLH1) 
exhibited similar biological functions, and were causative genes for 
Bowel, Breast, Ovarian and Womb cancer. All 4 cancers were 
associated with mutations of the same mutation classes. 
6. Four genes (i.e., ERBB4, MET, EGFR and ERBB2) exhibited 
similar biological functions, and 2 of these (i.e., EGFR and ERBB2) 
were causative Breast and Lung cancers and were associated with 
mutations of the same mutation classes (i.e. Missense/Nonsense). 
7. Four genes (i.e., CYP11A1, CYP19A, CYP1A1 and CYP1B1) 
exhibited similar biological functions, and are causative genes for 
Lung and Prostate cancers.  
 
In summary, the Missense/Nonsense mutation class may be a priority for 
researchers as this class is over-represented in the Human Cancer Map 
(HCM), Genome Wide Distribution Map, KEGG Pathway, Human genome, 
functional clustering of David Bioinformatics, and has a significant impact 
on human cancers. 
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Chapter Four  
 
4. Integrated Data Analytics of a Protein-Protein 
Interaction Map with Missense/ Nonsense Mutations 
of corresponding Genes 
Determination of the molecular cause of cancers has been a major 
focus of human genetic research since the early 1960s. The availability of 
advanced high-throughput genomic technologies and data has permitted 
large-scale genome-wide association studies (Cardon et al., 2007; 
Johnson and O'Donnell, 2009), and the analysis of complete DNA 
sequences of large numbers of cancer genomes to be conducted in order 
to gain understanding of how individual cancers develop (Stratton et al., 
2009).  
 
The aim of the work presented in this chapter was to associate 
genes based on the interactions of their encoded proteins. Specifically, 
gene sequences were interrogated for single base substitutions, which led 
to both a codon and amino acid change that was associated with cancer. 
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This approach was adopted to identify whether or not identical codon 
changes in two or more genes were associated with the same or different 
primary cancer type. For example, a codon change in the ATM gene, a 
switch from leucine to serine resulted in breast cancer, whereas the same 
codon change in the MSH2 gene resulted in bowel cancer.  
In order to gain greater knowledge of the associations between 
multiple genes related to cancer, and their single base substitutions I 
sought to:   
(i) Construct a Protein-Protein Interaction Map (PPIM) derived 
from 424 cancer-associated gene set using the Biological 
General Repository for Interaction Datasets (BioGRID) 
(www.thebiogrid.org).  
(ii) Extract Missense/Nonsense mutations (i.e. from codons with 
resultant amino acid change) for cancers.  
(iii) Investigate the distribution of changes in all 21 amino acids 














4.1. Protein-Protein Interaction Map (PPIM) 
 
A PPIM was constructed to investigate single base substitutions for 
the 424 gene set using BioGRID (Stark et al., 2011) and the GeneMANIA 
Cytoscape plugin (Montojo et al., 2010). Two genes were associated if 
they were found to interact with each other in a protein-protein interaction 
study. Here only the physical interactions of proteins were considered. 
These associating genes were then visualized using Gephi tools (Bastian 
et al., 2009) (see figure 4.1). The PPIM contains nodes that correspond to 
genes, the size of which (nodes) is proportional to the number of distinct 
genes connecting to it, while interconnected links (also called ‘edges’) 
represent the physical interaction of genes. The PPIM I obtained consisted 
of 292 genes with a total of 4,024 physical interactions among the 
corresponding proteins of genes. Certain genes tend to form a central hub 
connecting many other genes, where the distribution degree (k) is high. 
For example, TP53 (k=72), BRCA1 (k=55), CREBBP (k=56), ESR1 
(k=58), AR (k=27), ATM (k=22), BRCA2 (k=13) and RAD41 (k=28) all 
connect many other genes. These data indicate that each of these genes 
is highly interacted with others genes that encode proteins in the PPIM. 
However, a focus here was to identify Missense/Nonsense mutations in 
the DNA for every gene (that encoded a PPIM protein), whereby a single 
nucleotide causes a codon change, with a resultant unexpected amino 










Figure 4.1: Protein–Protein Interaction Map (PPIM): Nodes represent unique 
proteins, and the links (edges) identify the protein-protein physical interactions. 
The colour of the link indicates the originating or source node in the physical 









4.1.1. Interrogation of Missense/Nonsense Mutations of Codons and 
their encoded Amino Acid Changes in a PPIM-Informed 292 Cancer-
Associated Gene set  
The extraction of Missense/Nonsense mutations involving single 
nucleotide changes, which resulted in cancer-associated amino acid 
changes, was investigated manually for the 292-gene set informed by the 
PPIM. This was conducted one base at a time within the mutation using 
complementary data sources e.g., PubMed, OMIM (Amberger et al., 
2009), UniProtKB/Swiss-Port (Boutet et al., 2007) and HGMD(Stenson et 
al., 2009). The purpose of this Missense/Nonsense mutations data 
extraction was to detect:  
(i) the single base change in the affected codon  
(ii) the amino acid resulting from the altered codon  
(iii) the peptide position of the altered amino acid  
(iv) the associated cancer disorder(s) resulting from the altered 
amino acid using PubMed for every gene.  
In total, 2,851 Missense/Nonsense mutation records were found for 161 of 
the 292 interrogated genes and were stored as independent records for 
each gene symbol (see appendix 3 table 3.1). Thus, 131 genes informed 
by the PPIM did not have associated Missense/Nonsense mutation 
records. Thus, I was interested in next assessing whether identical amino 
acid alterations (e.g., a Ser to Leu, Ala to Leu, Tyr to Leu…. etc switch) for 
two or more genes within the 161-gene set were associated with the same 
primary cancer type.  
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4.1.2. Do Identical Amino Acid Alterations for two or more Genes 
Associated with the same Primary Cancer Type?  
 
To address whether identical amino acid alterations for two or more 
genes within the 161 genes set associate with the same primary cancer 
type, I combined the Missense/Nonsense mutation records with the map 
of interconnected gene nodes that informed the PPIM. This was achieved 
by: 
(i) Dividing the extracted Missense/Nonsense mutation records 
(table 3.1 appendix 3) into sub-tables, each consisting of 
records for one altered amino acid that was related to a 
primary cancer type. In total 21 tables were constructed for 
each of the 21 amino acid by running a string using R 
language.  
 
(ii) Associating the newly-constructed amino acid sub-table 
records with the PPIM connected nodes. This association 
was verified as follows. For two or more genes to be 
considered connected they must exhibit a physical 
interaction in the PPIM (recognized in BioGrid) and have an 
identically-altered amino acid that is also associated with the 
same primary cancer type. For example, the following two 
genes (TP53 and MSH2) are said to be associated where a 
single nucleotide change in TP53 changes the ‘GGC’ codon 
to ‘GAC’ resulting in a Glycine’ to ‘Aspartate’ amino acid 
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alteration to cause ‘Bowel cancer’, and a single nucleotide 
change in MSH2, resulting in a codon change from ‘TAT’ to 
‘GAT’, resulting in a ‘Tyrosine’ to ‘Aspartate’ amino acid 
change also causes ‘Bowel cancer’.  
(iii) Tagging the associated gene records by 0,1 or 2 where ‘0’ 
represents the same altered amino acid, ‘1’ the identical 
change in codon, and ‘2’ for the identical encoded amino 
acid change in the identical sequence position of the 
resultant peptide (appendix 3 table A.3.2).  
Due to the complex nature of biological data a manual verification 
process was carried out for combining and verifying each record 
successively, using the Gephi visualizing tools. This generated 21 
‘altered amino acid’ network maps involving 57 genes associated 
with 8 primary cancers (figures 4.2 to 4.22). 
 
As a navigation guide to the following 21 maps, the reader should note 
that:  
a) The colour of gene nodes represents the number of links (edges 
i.e. physical interactions). For any connecting two genes a blue 
edge represents the same altered amino acid (regardless of the 
nature of the codon change); a red edge represents identical 
codon change; and a green edge represents identical peptide 












Figure 4.2: PPIM of an Alanine altered amino acid and associated with the same 
primary cancer. 59% of the edges (red) show identical codon changes, while 
41% of the edges (blue) show non-identical codon changes. The width of the 
edge is proportional to the number of associated cancers between the two nodes. 
The name on the edge is the abbreviation of the primary cancer involved (e.g, 
Breast cancer (BRE) involves 59% of the connected edges, Bowel cancer (BOW) 










Figure 4.3: PPIM of an Arginine altered amino acid and associated with the 
same primary cancer. 52% of the edges (red) show identical codon changes, 
while 43% of the edges (blue) show non-identical codon changes and the 
remaining 5% of the edges (green) show identical peptide position of the altered 
amino acid. The width of the edge is proportional to the number of associated 
cancers between the two nodes. The name on the edge is the abbreviation of the 
primary cancer involved (e.g, Breast cancer (BRE) involves 38% of the 
connected edges, Bowel cancer (BOW) involves 43% of the connected edges, 
Lung cancer (LU) involves 4% of the connected edges, Ovarian cancer (OV) 
involves 9% of the connected edges and Stomach cancer (ST) involves 4% of 










Figure 4.4: PPIM of an Asparagine altered amino acid and associated with the 
same primary cancer. 60% of the edges (red) show identical codon changes, 
while 40% of the edges (blue) show non-identical codon changes. The width of 
the edge is proportional to the number of associated cancers between the two 
nodes. The name on the edge is the abbreviation of the primary cancer involved 
(e.g, Breast cancer (BRE) involves 53% of the connected edges, Bowel cancer 
(BOW) involves 33% of the connected edges, Ovarian cancer (OV) involves 7% 









Figure 4.5: PPIM of a Glutamate altered amino acid and associated with the 
same primary cancer. 88% of the edges (red) show identical codon changes, 
while 12% of the edges (blue) show non-identical codon changes. The width of 
the edge is proportional to the number of associated cancers between the two 
nodes. The name on the edge is the abbreviation of the primary cancer involved 
(e.g, Breast cancer (BRE) involves 44% of the connected edges and Bowel 
cancer (BOW) involves 56% of the connected edges). 
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Figure 4.6: PPIM of a Glycine altered amino acid and associated with the same 
primary cancer. 63% of the edges (red) show identical codon changes, while 
37% of the edges (blue) show non-identical codon changes. The width of the 
edge is proportional to the number of associated cancers between the two nodes. 
The name on the edge is the abbreviation of the primary cancer involved (e.g, 
Breast cancer (BRE) involves 63% of the connected edges, Bowel cancer (BOW) 
involves 32% of the connected edges and Ovarian cancer (OV) involves 5% of 
the connected edges). 
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Figure 4.7: PPIM of a Histidine altered amino acid and associated with the same 
primary cancer. 55% of the edges (red) show identical codon changes, while 
36% of the edges (blue) show non-identical codon changes and the remaining 
9% of the edges (green) show identical peptide position of the altered amino 
acid. The width of the edge is proportional to the number of associated cancers 
between the two nodes. The name on the edge is the abbreviation of the primary 
cancer involved (e.g, Breast cancer (BRE) involves 68% of the connected edges, 
Bowel cancer (BOW) involves 27% of the connected edges and Melanoma (ME) 
involves 5% of the connected edges). 
 
CHAPTER FOUR 





Figure 4.8: PPIM of an Isoleucine altered amino acid and associated with the 
same primary cancer. 48% of the edges (red) show identical codon changes, 
while 48% of the edges (blue) show non-identical codon changes and the 
remaining 4% of the edges (green) show identical peptide position of the altered 
amino acid. The width of the edge is proportional to the number of associated 
cancers between the two nodes. The name on the edge is the abbreviation of the 
primary cancer involved (e.g, Breast cancer (BRE) involves 48% of the 
connected edges, Bowel cancer (BOW) involves 48% of the connected edges 
and Ovarian cancer (OV) involves 4% of the connected edges). 
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Figure 4.9: PPIM of a Lysine altered amino acid and associated with the same 
primary cancer. 77% of the edges (red) show identical codon changes, while 
23% of the edges (blue) show non-identical codon changes. The width of the 
edge is proportional to the number of associated cancers between the two nodes. 
The name on the edge is the abbreviation of the primary cancer involved (e.g, 
Breast cancer (BRE) involves 46% of the connected edges, Bowel cancer (BOW) 
involves 31% of the connected edges and Ovarian cancer (OV) involves 23% of 
the connected edges). 
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Figure 4.10: PPIM of a Methionine altered amino acid and associated with the 
same primary cancer. 50% of the edges (red) show identical codon changes, 
while 50% of the edges (blue) show non-identical codon changes. The width of 
the edge is proportional to the number of associated cancers between the two 
nodes. The name on the edge is the abbreviation of the primary cancer involved 
(e.g, Breast cancer (BRE) involves 63% of the connected edges, Bowel cancer 
(BOW) involves 31% of the connected edges and Ovarian cancer (OV) involves 









Figure 4.11: PPIM of a Proline altered amino acid and associated with the same 
primary cancer. 53% of the edges (red) show identical codon changes, while 
40% of the edges (blue) show non-identical codon changes and the remaining 
7% of the edges (green) show identical peptide position of the altered amino 
acid. The width of the edge is proportional to the number of associated cancers 
between the two nodes. The name on the edge is the abbreviation of the primary 
cancer involved (e.g, Breast cancer (BRE) involves 54% of the connected edges, 
Bowel cancer (BOW) involves 40% of the connected edges and Ovarian cancer 
(OV) involves 6% of the connected edges). 
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Figure 4.12: PPIM of a Termination (stop codon) altered amino acid and 
associated with the same primary cancer. 50% of the edges (red) show identical 
codon changes, while 31% of the edges (blue) show non-identical codon 
changes and the remaining 19% of the edges (green) show identical peptide 
position of the altered amino acid. The width of the edge is proportional to the 
number of associated cancers between the two nodes. The name on the edge is 
the abbreviation of the primary cancer involved (e.g, Breast cancer (BRE) 
involves 63% of the connected edges, Bowel cancer (BOW) involves 25% of the 
connected edges, Ovarian cancer (OV) involves 6% of the connected edges and 
Prostate cancer (PR) involves 6% of the connected edges). 
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Figure 4.13: PPIM of a Threonine altered amino acid and associated with the 
same primary cancer. 73% of the edges (red) show identical codon changes, 
while 20% of the edges (blue) show non-identical codon changes and the 
remaining 7% of the edges (green) show identical peptide position of the altered 
amino acid. The width of the edge is proportional to the number of associated 
cancers between the two nodes. The name on the edge is the abbreviation of the 
primary cancer involved (e.g, Breast cancer (BRE) involves 53% of the 
connected edges, Bowel cancer (BOW) involves 40% of the connected edges 









Figure 4.14: PPIM of a Tyrosine altered amino acid and associated with the 
same primary cancer. 73% of the edges (red) show identical codon changes, 
while 27% of the edges (blue) show non-identical codon changes. The width of 
the edge is proportional to the number of associated cancers between the two 
nodes. The name on the edge is the abbreviation of the primary cancer involved 
(e.g, Breast cancer (BRE) involves 45% of the connected edges, Bowel cancer 
(BOW) involves 45% of the connected edges and Ovarian cancer (OV) involves 
5% of the connected edges). 
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Figure 4.15: PPIM of a Serine altered amino acid and associated with the same 
primary cancer. 67% of the edges (red) show identical codon changes, while 
33% of the edges (blue) show non-identical codon changes. The width of the 
edge is proportional to the number of associated cancers between the two nodes. 
The name on the edge is the abbreviation of the primary cancer involved (e.g, 
Breast cancer (BRE) involves 47% of the connected edges, Bowel cancer (BOW) 
involves 37% of the connected edges, Ovarian cancer (OV) involves 3% of the 











Figure 4.16: PPIM of an Aspartate altered amino acid and associated with the 
same primary cancer. 71% of the edges (red) show identical codon changes, 
while 29% of the edges (blue) show non-identical codon changes. The width of 
the edge is proportional to the number of associated cancers between the two 
nodes. The name on the edge is the abbreviation of the primary cancer involved 
(e.g, Breast cancer (BRE) involves 50% of the connected edges, Bowel cancer 
(BOW) involves 36% of the connected edges and Ovarian cancer (OV) involves 

















Figure 4.17: PPIM of a Cysteine altered amino acid and associated with the 
same primary cancer. 77% of the edges (red) show identical codon changes, 
while 23% of the edges (blue) show non-identical codon changes. The width of 
the edge is proportional to the number of associated cancers between the two 
nodes. The name on the edge is the abbreviation of the primary cancer involved 
(e.g, Breast cancer (BRE) involves 53% of the connected edges, Bowel cancer 
(BOW) involves 23% of the connected edges, Ovarian cancer (OV) involves 9% 
of the connected edges, Stomach cancer (ST) involves 5% of the connected 
edges, Melanoma  (ME) involves 5% of the connected edges and Prostate 










Figure 4.18: PPIM of a Glutamine altered amino acid and associated with the 
same primary cancer. 65% of the edges (red) show identical codon changes, 
while 32% of the edges (blue) show non-identical codon changes and the 
remaining 3% of the edges (green) show identical peptide position of the altered 
amino acid. The width of the edge is proportional to the number of associated 
cancers between the two nodes. The name on the edge is the abbreviation of the 
primary cancer involved (e.g, Breast cancer (BRE) involves 58% of the 
connected edges, Bowel cancer (BOW) involves 30% of the connected edges, 
Ovarian cancer (OV) involves 3% of the connected edges, Stomach cancer (ST) 











Figure 4.19: PPIM of a Leucine altered amino acid and associated with the same 
primary cancer. 44% of the edges (red) show identical codon changes, while 
56% of the edges (blue) show non-identical codon changes. The width of the 
edge is proportional to the number of associated cancers between the two nodes. 
The name on the edge is the abbreviation of the primary cancer involved (e.g, 
Breast cancer (BRE) involves 56% of the connected edges, Bowel cancer (BOW) 
involves 31% of the connected edges, Ovarian cancer (OV) involves 5% of the 
connected edges, Stomach cancer (ST) involves 3% of the connected edges and 









Figure 4.20: PPIM of a Phenylalanine altered amino acid and associated with 
the same primary cancer. 58% of the edges (red) show identical codon changes, 
while 42% of the edges (blue) show non-identical codon changes. The width of 
the edge is proportional to the number of associated cancers between the two 
nodes. The name on the edge is the abbreviation of the primary cancer involved 
(e.g, Breast cancer (BRE) involves 75% of the connected edges, Bowel cancer 
(BOW) involves 10% of the connected edges, Ovarian cancer (OV) involves 10% 










Figure 4.21: PPIM of a Tryptophan altered amino acid and associated with the 
same primary cancer. 61% of the edges (red) show identical codon changes, 
while 39% of the edges (blue) show non-identical codon changes. The width of 
the edge is proportional to the number of associated cancers between the two 
nodes. The name on the edge is the abbreviation of the primary cancer involved 
(e.g, Breast cancer (BRE) involves 42% of the connected edges, Bowel cancer 
(BOW) involves 48% of the connected edges and Ovarian cancer (OV) involves 
10% of the connected edges). 
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Figure 4.22: PPIM of a Valine altered amino acid and associated with the same 
primary cancer. 36% of the edges (red) show identical codon changes, while 
56% of the edges (blue) show non-identical codon changes and the remaining 
8% of the edges (green) show identical peptide position of the altered amino 
acid. The width of the edge is proportional to the number of associated cancers 
between the two nodes. The name on the edge is the abbreviation of the primary 
cancer involved (e.g, Breast cancer (BRE) involves 60% of the connected edges, 
Bowel cancer (BOW) involves 24% of the connected edges, Ovarian cancer (OV) 
involves 8% of the connected edges, Lung cancer (LU) involves 4% of the 









4.1.3. Investigating the Connectivity of the 21 Individual PPIM Altered 
Amino Acid Networks. 
The ‘altered amino acid networks’ revealed several interesting 
points. Identical single nucleotide changes, identical altered amino acid, 
and identical peptide positions of the altered amino acids were found in 
several connected gene nodes. These data may be best presented in four 
parts on the basis of their sub-network connectivity. For example in the 
first part two fully-disconnected sub-networks occur with no bridging node, 
while in the second these disjointed sub-networks are bridged by BRCA1 
and MSH6, the third bridged by TP53 and MSH2, and finally the fourth 
bridged by CHEK2 and MSH2. 
  
1. a) Fig. 4.2-4.14 shows two fully disconnected sub-networks, 
where one sub-network corresponds to connected genes 
associated with Bowel cancer and the other sub-network to Breast 
cancer. Both sub-networks also contain, a minor constituent 
ovarian, prostate, lung and melanoma cancers. Connected gene 
nodes in these networks were associated with the same amino acid 
alteration and/or the identical change of codon. Surprisingly some 
of these changes occurred at identical peptide positions in the 
proteins encoded by the connected genes. For example, Figure 4.7 
shows that the amino acid encoded by the BRCA1 gene altered 
from ‘Asn564’ to ‘His564’, the amino acid change for the protein 
encoded by the BARD1 gene was from ‘Gln564’ to ‘His564’. Both 
amino acid alterations are associated with Breast cancer. This 
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finding was agreed by a previous report showing interactions of 
these two genes in Breast cancer (Wu et al., 1996), indicating that 
the BARD1/BRCA1 interaction is interrupted by BRCA1 Missense 
mutations. Others have reported that BRCA1 DNA-binding activity 
is stimulated by BARD1 (Simons et al., 2006).  I also detected 
another amino acid alteration in BRCA1 i.e., ‘Gln1785’ to ‘His1785’ that 
was also found in the ATM i.e., ‘Pro1785’ to ‘His1785’ both associated 
with Breast cancer. It has been reported that DNA damage can lead 
to ATM-dependent phosphorylation of BRCA1 leading to Breast 
cancer (Gatei et al., 2000; Cortez et al., 1999).  
 
1.b) Fig 4.13 and 4.8 shows where BRCA1 and BRCA2 have an 
identically changed codon (i.e. ‘ATG’ to ‘ACG’) that alters the 
resultant amino acid from ‘Met’ to ‘Thr’ in the same peptide 
sequence position 1. This change is associated with Ovarian 
cancer. An identical codon change from ‘ATG’ to ‘ATA’ produced a 
‘Met’ to ‘Ile’ alteration in same peptide also at position ‘1’. In this 
case the change was associated with Breast cancer. It has 
previously been reported that BRCA1 and BRCA2 proteins interact 
in pathways that lead to the activation of double-strand break repair 
and homologous recombination (Chen et al., 1998).  
 
1. c) Fig 4.11 reveals an amino acid alteration ‘Ala636’ to ‘Pro636’ in 
MSH2, while a ‘Leu636’ to ‘Pro636’ amino acid alteration was 
apparent for MLH1. Both changes are associated with Bowel 
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cancer. Both genes also exhibit another identical amino acid 
alteration ‘Gly751’ to ‘Arg751’ in MSH2 and ‘Lys751’ to ‘Arg751’ in 
MLH1, again both associated with Bowel cancer. According to 
previous reports these two genes are pathway genes for bowel 
cancer (Arends, 2013).  
2. a) Fig 4.15, 4.20, 4.21 and 4.22 illustrate how two disjointed sub-
networks can be connected by an identical codon or amino acid alteration.  
These network’s ‘bridges’ may be a cross point for the clustering of breast 
and bowel cancers. For example, BRCA1 and MSH6 have 4 identical 
codon changes each resulting in an amino acid change. These include: (i) 
Fig 4.15 shows a ‘TCT’ to ‘TTT’ codon change resulting in an amino acid 
alteration from ‘Ser’ to ‘Phe’, which is associated with Breast cancer; (ii) 
Fig 4.20 shows a ‘GCC’ to ‘TCC’ codon change resulting in an ‘Ala’ to ‘Ser’ 
amino acid change also leading to Breast cancer; (iii) Fig 4.21 showing a 
‘CGG’ to ‘TGG’ codon change leading to a ‘Arg’ to ‘Trp’ amino acid change 
that in this case is associated Bowel cancer. Fig 4.22 shows a change in 
amino acid from ‘Ile’ to ‘Val’ for BRCA1 and MSH6 that is associated with 
Breast cancer.  
BRCA1 is connected with two other genes (MSH2 and MLH1) as 
they are associated with Bowel cancer. The literature reports that MSH6, 
MSH2 and MLH1 genes are associated with BRCA1 to form a large 
protein complex for the recognition of abnormal/damaged DNA structures 








3) Fig 4.16, 4.17 and 4.19 reveal networks with two disjoined sub-
networks that are bridged with a TP53 and MSH2 connection. Both genes 
share an identical codon change that produces different amino acids. In 
Fig 4.16 this is ‘GGC’ to ‘GAC’ resulting in ‘Gly’ to ‘Asp’ switch, while in Fig 
4.19 the change of codon is from ‘CCC’ to ‘CTC’, with resultant ‘Pro’ to 
‘Leu’ switch. Both changes are associated with Bowel cancer. By contrast, 
Fig 4.17 shows another sub-network linked this time by TP53 and MSH2. 
The encoded protein TP53 is altered via the amino acid change ‘Arg’ to 
‘Cys’, while for MSH2 ‘Tyr’ is altered to ‘Cys’; both changes are associated 
with Stomach cancer. The literature reports that these two genes bind 
together during the DNA synthesis phase of the cell cycle (Zink et al., 
2002).  
4) Fig 4.18 shows an identical codon change in CHEK2 and MSH2 
that connect the two disjoined sub-networks. Here the codon has changed 
from ‘CGG’ to ‘CAG’ in both genes, resulting in a ‘Arg’ to ‘Gln’ switch and 
is associated with Bowel cancer. The literature reports that MSH2 binds  
















The main objectives of this chapter were as follows: (i) associating 
genes based on the physical interactions of their encoded proteins and 
thereby construct a protein-protein interaction map (PPIM), (ii) extracting 
Missense/Nonsense mutations in codons and determine their associated 
amino acid changes, and relating these to associated cancers within the 
PPIM, (iii) merging the extracted Missense/Nonsense mutation records 
with the PPIM data to construct “21 amino acid alteration networks”, and 
lastly; (iv) investigating the influence of a single nucleotide change, amino 
acid change and the peptide position of the changed amino acid in the 
altered amino acid networks.  
 
The amino acid alteration networks revealed:   
1. Mutation-derived alterations in Alanine, Arginine, Asparagine, 
Glutamate, Histidine, Isoleucine, Lysine, Methionine, Proline, 
Termination, Threonine and Tyrosine were associated with two 
fully-disjoint sub-networks; the first sub-network associated with 
genes linked to Bowel cancer and the second sub-network 
associated with genes leading to Breast cancer. 
2. Mutation-derived alterations in Serine, Aspartate, Cysteine, 
Glutamine, Leucine, Phenylalanine, Tryptophan and Valine 
connected the two disjoint sub-networks and linked the clusters of 
Bowel, Breast or Stomach cancers. 
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3. BRCA1 and MSH6 appear to play a central role in connecting the 
disjoint sub-networks of mutation-derived alterations in Serine, 
Phenylalanine, Tryptophan and Valine, where both genes are 
associated with Breast and Bowel cancers. 
4. TP53 and MSH2 connect disjointed sub-networks by the encoded 
amino acid alterations in Leucine and Aspartate, resulting in Bowel 
cancer, while the encoded amino acid alteration leading to Cysteine 
was associated with Stomach cancer. 
5. CHEK2 and MSH2 genes connect genes in the disjointed sub-
networks, but the encoded amino acid change to Glutamine, 
resulting in Bowel cancer. 
6. Identical encoded amino acid change at identical peptide sequence 
positions for two associated genes leading to same cancer. 
 
It may be useful to further investigate the groups of associated genes 
in these altered amino acid networks, and especially those gene nodes 
that connect disjointed gene node clusters in the network. Areas of 
potential relevant research could be around their enzyme binding, gene 
ontology, damaged DNA binding and DNA repair etc.  
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Chapter Five  
 
5. Overall Discussion and Future Work 
 
5.1. General Conclusions 
The aim of this project was to assess the involvement of germline 
mutation classes in developing human cancers. This aim was progressed 
via several specific objectives/questions as follows: (i) Are individual 
groups of primary cancers associated with specific gene subsets groups 
(within the 424 cancer genes)? (ii) Are there any specific groups of primary 
cancers associated with particular mutation classes? (iii) If both questions 
prove true, are groups of cancers associated with particular mutation 
classes of target gene groups? This project also explored whether a 
corresponding Protein-Protein Interaction Map, derived from the 
Missense/Non-sense Mutation portion of the HCM gene set, would provide 
further information on gene associations between primary cancers in 
terms of the consequent identical amino acid changes involved.   
Results showed that: (1) Closely-connected human cancers in the 
HCM exhibited a strong association with particular mutation class.  (2) 
Missense /Nonsense and Regulatory mutations played a central role in 
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connecting cancers (i.e. via primary cancer nodes) and so significantly 
influenced the construction of the HCM. (3) Group of genes with 
Missense/Nonsense and Regulatory mutations tended to be cancer-
associated pathway genes. (4) BRCA1, BRCA2, PALB2, MSH2, MSH6, 
MLH1, CDKN2A, and TP53 showed the highest agreement for 5 of 10 
mutation classes. (5) From the PPIM, it was evident that BRCA1, MSH6, 
BARD1, TP53, MSH2 and CHEK2 proteins best connected Breast, 
Ovarian, Prostate and Bowel primary cancers and so could represent 
‘driver proteins’ for these cancers.   
In summary, this project has approached the analysis of gene 
involvement in human primary cancers from the starting position of the 
mutation class that harbours the specific gene mutation. Together with 
their downstream resultant alterations in the associated proteins, this 
analysis provides great insights into the relatedness of primary human 
cancers and their associated potential gene hierarchies. The data 
produced in this study may therefore help us to understand further the 
aetiology, diagnosis and potentially personalized treatments for cancer. 
For example, the amino acids connecting the disjoined networks via 
different genes and cancers at the missense/nonsense mutation might be 
a point where one gene is affected leading to an effect on all linked genes 
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5.2. General Discussion  
The Human Cancer Map (HCM) revealed a significant variation in 
the dominance of different mutation class involved in cancer. 
Missense/Nonsense mutation (44%) represented almost half of the 
interconnections in the HCM, followed by small deletion mutations at 14%. 
The remaining mutation classes ranged from 10% to 1%. This means that 
cancer associations vary from one mutation class to another. For example, 
a total of 19 primary cancers with Missense/Nonsense mutation were 
found to be associated to each other, whereas only 12 primary cancers 
were represented by splicing mutations.  
The agreements between the connected nodes (cancers) in the 
HCM and sub-HCMs (i.e. sub-MAPs for each mutation class) were 
examined and quantified using Choen’s kappa test (Carletta, 1996; 
Cohen, 1960), and revealed some interesting results. Cancer node 
connectivity levels involving Missense/Nonsense and the Regulatory 
mutation classes ranged from low for 80% of the nodes (k<0.25) to 
moderate for 20% (k=0.25-0.5). This suggests that although this mutation 
class dominates the HCM, it may be less important mutations in terms of 
connectivity between cancer nodes in the constructed HCM (Chapter 3, 
Figure 3.13). However, many more of these genes are involved in 
pathways (KEGG) for cancers and other disorders than for other mutation 
classes, even if the later show higher levels of kappa agreement (Chapter 
3, Figure 3.26 and Table 3.1).  By contrast, mutations involving Repeat 
variations, Complex rearrangement and Gross insertions showed low 
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agreement values for all the connected nodes, which make them less 
important mutations in terms of connectivity between cancer nodes in the 
constructed HCM. (Chapter 3, Figure 3.13 and Appendix 1 Tables A.1.8, 
A.1.9 and A.1.10). Furthermore, these gene nodes were not represented 
in the KEGG pathways for cancer. Surprisingly, while the remaining five 
mutation classes showed some high kappa agreement values between 
interconnected gene nodes, the mutation class was represented in only a 
small proportion of all nodes (Fig. 3.13). For example, while Small Indels 
mutations represented only a mere 2% of the total HCM, their 
corresponding inter-node connectivity revealed 100% high or very high 
kappa values (agreement) (Chapter 3, Figure 3.13 and Appendix 1 Tables 
A.1.2, A.1.3, A.1.4, A.1.6 and A.1.7).   
From a biological perspective, what does the above finding mean? I 
would like to suggest two potential hypotheses. The first indicates that a 
Missense/Nonsense and Regulatory mutation has a large impact on how 
cancer nodes associate with each other in a HCM. Without the 
involvement of these two mutation classes the HCM would fragment, and 
almost 50% of cancer nodes would be disconnected. This then may 
suggest that mutations of these 2 classes may contain driver mutations 
connecting cancer gene nodes. Alternatively, mutations of the following 
types (i.e. Small Deletions, Splicing, Small Insertions, Gross Deletions, 
and Small Indels), with their high to very high agreements (kappa values) 
between some of their connected cancer nodes, may make them more 
deleterious as they would have greater impact on cancer gene 
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connectivity in the HCM. For example, Small deletion mutations tend to be 
a target mutation connecting Womb cancer to Lymphoma and Brain 
cancer nodes via small deletion mutations in the BRCA2, BRCA1 and 
PALB2 genes, while at the same time connecting Lymphoma to Brain 
cancer nodes via small deletion mutations in MSH2, MSH6, BRCA1 and 
MLH1 (figure 3.3 and Appendix 1 Table A1.2). Splicing mutations tend to 
be target mutations for connecting Melanoma to Brain and Pancreatic 
cancer nodes via splicing mutations in the CDKN2A gene, and for 
connecting Breast to Ovarian cancer nodes via splicing mutations in 
BRCA1, BRCA2, RAD51C, RAD51D and TP53 genes. They also connect 
Kidney to Bladder cancer nodes via splicing mutations in MSH2 (Figure 
3.4 and Appendix 1 Table A1.3). 
Small Insertion mutations tend to be more engaged in the HCM by 
targeting more high to very high agreements (kappa values) between their 
inter-connected cancer nodes. For example, Stomach cancer connected 
to Bowel and Kidney cancers via small Insertion mutations in CDH1 and 
MSH2, while Breast cancer connected to Ovarian cancer via small 
Insertion mutations BRCA1, BRIP1 and RAD51C. Melanoma was 
connected to Lung, Prostate and Pancreatic cancers via small Insertion 
mutations of BRCA2 and CDKN2A, while Pancreatic cancer was connect 
to Prostate and Lung by small Insertion mutations in BRCA2 ( Figure 3.5 
and Appendix 1 Table A1.4). 
Finally, Small Indels mutation tend to have a high to very high 
agreements (100%) between all its connected cancer nodes, such as 
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Bowel connected to the Brain and Womb cancer nodes via MLH1 and 
MSH6, Ovarian connected to Breast and Pancreatic cancer node via 
BRCA1 and BRCA2, Melanoma connected to the Head and Neck cancer 
node via CDKN2A (Figure 3.8 and Appendix 1 Table A1.7). 
The above five mutation classes may share some similarities in 
terms of their genetics implications via associated mutations in BRCA1, 
BRCA1, PALB2, MSH6, MSH2, MLH1, CDKN2A, RAD51C, RAD51D, 
TP53, CDH1 and BRIP1. These 12 genes were also connected in the 
Genome-wide Distribution Maps and also at the protein interaction as 
shown in the Protein-Protein Interactions Map (PPI). DAVID analysis 
revealed that 2 of these twelve genes (i.e., MSH6 and MLH1) tended to 
have similar biological functions. All these revealed information suggesting 
these groups of genes could be the main driver genes, which are 
responsible for many types of cancers as shown in this study. These 
relations can be seen in Chapter 3, figures 3.16 to 3.24 and Chapter 4 
figure 4.1. 
The results of this study suggested that Missense/Nonsense 
mutations have a large influence in interconnecting cancer nodes, and 
interrogation of these Missense/Nonsense mutation records provided new 
insights. One of these is that cancers caused by different amino acid 
alterations involving all 21 amino acids of the human body. The 
interrogation results targeted two groups of interconnected genes; each 
one formed a network associated with a specific cancer. The first group of 
connected genes (MSH2, PMS2, MLH1, MSH6 and MUTYH) associated 
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with Bowel cancer, while the second group of genes (PALB2, BRCA1, 
BRCA2, ATM, TP53 and CHEK2) associated with Breast cancer. These 
PPIM networks occur when their nucleotide changes encode alterations in 
one of the following 13 amino acids (i.e., Alanine, Arginine, Asparagine, 
Glutamate, Glycine, Histidine, Isoleucine, Lysine, Methionine, Proline, 
Termination, Threonine and Tyrosine) (Chapter 4 figures 4.2 to 4.14). But 
when these two groups of genes undergo nucleotide change to encode 
one of the following 8 amino acids (i.e., Serine, Aspartate, Cysteine, 
Glutamine, Leucine, Phenylalanine, Tryptophan and Valine) we see 
merging of the two disjointed node clusters in the network. The bridging is 
either by Breast, Bowel or Ovarian cancer (figures 4.15 to 4.22), and could 
be a interesting subject for further research as these 12 genes appeared 
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5.3. Future Work 
It would be potentially very useful to extending the current study 
presented in this thesis by considering the following important points: 
1. Extending current work on the HCM, which currently includes 20 
primary human cancers and their associated 424 genes (of a total of 
29 primary human cancers), by including updated information of 
genes, cancers and mutation records. This will allow us to produce a 
global HCM.  
2. Extending the current interrogation protocol used for 
Missense/Nonsense mutation class to the remaining nine mutation 
classes i.e. Splicing, Small deletions, Small Insertion, Small Indels, 
Complex Rearrangement, Gross deletion, Gross Insertion, 
Regulatory and Repeat variation. 
3. Investigating the environmental factors that have impact on gene 
behaviour, which will address unanswered questions in relation to 
genetic mutations. This will allow us to produce a modified Global 
Human Cancer Map. 
4. Integrating somatic cell mutations and germline mutations. 
5. Investigating further the following highly represented cancer-related 
genes i.e. MSH2, PMS2, MLH1, MSH6, MUTYH, PALB2, BRCA1, BRCA2, 
ATM, TP53 and CHEK2) in terms of their associated biological 
activities e.g., enzyme binding, gene ontology, Damage DNA binding 
and DNA repair etc. 
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6. Expands the current work presented in chapter three (figure 3.15), to 
include a patient based clinical data and increase to the number of 
gene, mutation and cancer records.  
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Table A.1.1: Missense/Nonsense SM-HCM. The first column represents cancer 
node one, the second column is the associated cancer node for cancers in 
column one, the third column is the shared gene for each of the two associated 
cancer nodes, the fourth column is the kappa agreement test results where low 
agreements <0.25, moderate agreement 0.25 to 0.50, high agreement 0.50 to 
0.75 and the very high agreement 0.75 – 1. In total there are 56 genes and 19 
primary cancer nodes.  
Cancer Node1 Cancer Node 2 Shared Genes Kappa 
Lung Cancer Prostate Cancer CYP1B1 -0.20 
Bowel Cancer Breast Cancer NBN,TP53,MSH6,PML,BRCA
1,BRCA2,CHEK2,PARP1 
-0.17 
Bowel Cancer Ovarian Cancer TP53,BRCA1,BRCA2,CHEK2 -0.14 
Lung Cancer Bowel Cancer ABCB1,AXIN2,CYP1A1,NBN,
OGG1,TP53,XPC 
-0.14 
Lung Cancer Ovarian Cancer BARD1,TNFRSF10A,TP53 -0.14 
Lung Cancer Melanoma NBN -0.14 
Bowel Cancer Pancreatic Cancer BRCA2 -0.13 
Lung Cancer Breast Cancer ATM,BARD1,EGFR,ERBB2,N
BN,TP53,XRCC1 
-0.09 
Breast Cancer Melanoma NBN,BRCA2 -0.07 
Lung Cancer Stomach Cancer TP53 -0.07 
Melanoma Ovarian Cancer BRCA2 -0.07 
Bowel Cancer Skin Cancer (Non Melanoma) TP53 -0.06 
Bowel Cancer Kidney Cancer FLCN,MSH2 -0.05 
Kidney Cancer Ovarian Cancer GEMIN4 -0.05 
Skin Cancer(Non Melanoma) Breast Cancer TP53 -0.05 
Breast Cancer Pancreatic Cancer BRCA2,FANCA -0.04 
Bowel Cancer Brain tumours TP53,MSH2 -0.02 
Breast Cancer Head and neck cancer EGFR -0.02 
Breast Cancer Oesophageal Cancer AURKA -0.02 
Melanoma Prostate Cancer BRCA2 -0.02 
Ovarian Cancer Brain tumours TP53 -0.02 
Womb Cancer Ovarian Cancer BRCA1 -0.02 
Bowel Cancer Melanoma NBN,BMP4,BRCA2 -0.01 
Breast Cancer Stomach Cancer TP53,CDH1 0.00 
Breast Cancer Brain tumours TP53,PTPN11 0.00 








Prostate Cancer Pancreatic Cancer BRCA2 0.01 
Skin Cancer(Non Melanoma) Ovarian Cancer TP53 0.01 
Lung Cancer Brain tumours TP53,BAP1 0.02 
Stomach Cancer Prostate Cancer CDH1 0.03 
Womb Cancer Prostate Cancer BRCA1 0.03 
Bowel Cancer Soft Tissue Sarcomas TP53 0.04 
Kidney Cancer Melanoma CDKN2A 0.04 
Lung Cancer Bladder Cancer XPC 0.04 
Ovarian Cancer Lymphoma TP53 0.04 
Bowel Cancer Lymphoma TP53,MET 0.05 
Bowel Cancer Leukaemia BUB1B,MYO18B 0.05 
Bowel Cancer Oesophageal Cancer MLH3,PTGS2 0.05 
Lung Cancer Soft Tissue Sarcomas TP53 0.06 
Lung Cancer Mouth Oropharyngeal Cancer XRCC4 0.06 
Breast Cancer Lymphoma ATM,TP53 0.07 
Pancreatic Cancer Ovarian Cancer BRCA2,PALB2 0.07 
Bowel Cancer Bladder Cancer XPC,ERCC6 0.08 
Bowel Cancer Prostate Cancer BRCA1,BRCA2,CHEK2,EPHB
2,PARP1 
0.08 
Lung Cancer Lymphoma ATM,TP53 0.09 
Lung Cancer Head and neck cancer EGFR,PTPN13 0.09 
Lung Cancer Womb Cancer MGMT 0.09 
Skin Cancer(Non Melanoma) Melanoma MC1R 0.10 
Ovarian Cancer Soft Tissue Sarcomas TP53 0.11 
Stomach Cancer Ovarian Cancer TP53,CDH1 0.11 
Stomach Cancer Brain tumours TP53 0.12 
Stomach Cancer Womb Cancer MLH1 0.12 
Bowel Cancer Stomach Cancer TP53,MET,NUDT1,MLH1 0.14 
Bowel Cancer Womb Cancer MSH6,BRCA1,MLH3,MLH1 0.14 
Head and neck cancer Melanoma P14ARF 0.14 
Melanoma Leukaemia RMI1 0.14 
Lung Cancer Skin Cancer(Non Melanoma) TP53,TP53BP1 0.15 
Skin Cancer(Non Melanoma) Lung Cancer ERCC2 0.15 
Head and neck cancer Pancreatic Cancer P14ARF 0.16 
Skin Cancer(Non Melanoma) Stomach Cancer TP53 0.16 
Skin Cancer(Non Melanoma) Brain tumours TP53 0.16 
Brain tumours Lymphoma TP53 0.20 
Womb Cancer Oesophageal Cancer MLH3 0.20 
Prostate Cancer Ovarian Cancer BRCA1,BRCA2,CHEK2,CDH1 0.21 
Skin Cancer(Non Melanoma) Lymphoma TP53 0.24 
Kidney Cancer Pancreatic Cancer VHL,CDKN2A 0.25 
Breast Cancer Prostate Cancer BRCA1,BRCA2,CHEK2,PARP
1,AR,CDH1,CYP19A1 
0.27 
Kidney Cancer Brain tumours MSH2,SDHB 0.29 
Breast Cancer Soft Tissue Sarcomas TP53 0.31 
Soft Tissue Sarcomas Brain tumours TP53 0.31 
Stomach Cancer Soft Tissue Sarcomas TP53 0.31 




Skin Cancer(Non Melanoma) Soft Tissue Sarcomas TP53 0.38 
Melanoma Pancreatic Cancer BRCA2,P14ARF,CDKN2A 0.39 
Stomach Cancer Lymphoma TP53,MET 0.46 








Table A.1.2: Small Deletions SM-HCM. The first column represents cancer node 
one, the second column is the associated cancer node for cancers in column 
one, the third column is the shared gene for each of the two associated cancer 
nodes, the fourth column is the kappa agreement test results where low 
agreements <0.25, moderate agreement 0.25 to 0.50, high agreement 0.50 to 
0.75 and the very high agreement 0.75 – 1. In total there are 19 genes and 12 











Cancer Node 1 Cancer Node 2 Genes Kappa 
Bowel Cancer Breast Cancer CDKN2A -0.51 
Bowel Cancer Ovarian Cancer MSH2 -0.24 
Bowel Cancer Pancreatic Cancer BRCA2,BRCA1,PALB2 -0.14 
Breast Cancer Pancreatic Cancer MSH2,MSH6,BRCA1,MLH1 -0.08 
Lung Cancer Breast Cancer MSH2 -0.04 
Lung Cancer Ovarian Cancer BRCA2 -0.04 
Prostate Cancer Ovarian Cancer CDKN2A -0.04 
Womb Cancer Ovarian Cancer MSH2,MSH6 -0.04 
Lung Cancer Bowel Cancer MSH2,MSH6 0.10 
Breast Cancer Stomach Cancer BRCA2,SERCA2B 0.11 
Lung Cancer Pancreatic Cancer BRCA2,BRCA1,PALB2 0.18 
Prostate Cancer Pancreatic Cancer MSH2 0.18 
Pancreatic Cancer Ovarian Cancer BRCA2,SERCA2B 0.19 
Breast Cancer Prostate Cancer MSH2,MSH6 0.22 
Bowel Cancer Lymphoma 
BRCA2,BRCA1,BRIP1,CDH1,CHEK2,RA
D50,RAD51C,TP53 0.24 
Bowel Cancer Brain tumours BRCA2,SERCA2B 0.24 
Bowel Cancer Bladder Cancer BRCA2 0.24 
Melanoma Pancreatic Cancer 
BRCA2,BRCA1,BRIP1,CDH1,CHEK2,RA
D50,RAD51C,TP53 0.32 
Breast Cancer Ovarian Cancer 
BRCA2,BRCA1,BRIP1,CDH1,CHEK2,RA
D50,RAD51C,TP53 0.42 
Lung Cancer Prostate Cancer CDKN2A 0.42 
Bowel Cancer Womb Cancer MSH2,MSH6,BRCA1,MLH1 0.46 
Womb Cancer Lymphoma BRCA2,BRCA1,PALB2 0.63 
Womb Cancer Brain tumours BRCA2 0.63 








Table A.1.3: Splicing SM-HCM. The first column represents cancer node one, the 
second column is the associated cancer node for cancers in column one, the 
third column is the shared gene for each of the two associated cancer nodes, the 
fourth column is the kappa agreement test results where low agreements <0.25, 
moderate agreement 0.25 to 0.50, high agreement 0.50 to 0.75 and the very high 
agreement 0.75 – 1. In total there are 12 genes and 12 primary cancer nodes. 
Cancer Node 1 Cancer Node 2 Genes Kappa 
Prostate Cancer Ovarian Cancer BRCA2 -0.09 
Breast Cancer Pancreatic Cancer BRCA2 0.00 
Pancreatic Cancer Ovarian Cancer BRCA2 0.06 
Breast Cancer Prostate Cancer BRCA2,CHEK2 0.17 
Bowel Cancer Stomach Cancer MUTYH 0.25 
Prostate Cancer Pancreatic Cancer BRCA2 0.25 
Stomach Cancer Prostate Cancer CDH1 0.25 
Brain tumours Pancreatic Cancer CDKN2A 0.40 
Bowel Cancer Womb Cancer MSH6 0.43 
Bowel Cancer Kidney Cancer MSH2 0.43 
Bowel Cancer Bladder Cancer MSH2 0.43 
Melanoma Brain tumours CDKN2A 0.63 
Melanoma Pancreatic Cancer CDKN2A 0.63 
Skin Cancer(Non Melanoma) Brain tumours SUFU 0.63 
Breast Cancer Ovarian Cancer 
BRCA1,BRCA2,RAD5
1C,RAD51D,TP53 0.83 






























Table A.1.4: Small Insertion SM-HCM. The first column represents cancer node 
one, the second column is the associated cancer node for cancers in column 
one, the third column is the shared gene for each of the two associated cancer 
nodes, the fourth column is the kappa agreement test results where low 
agreements <0.25, moderate agreement 0.25 to 0.50, high agreement 0.50 to 
0.75 and the very high agreement 0.75 – 1. In total there are 9 genes and 10 
primary cancer nodes. 
Cancer Node 1 Cancer Node 2 Genes Kappa 
Bowel Cancer Breast Cancer CDH1 -0.35 
Breast Cancer Stomach Cancer CDH1 0.05 
Melanoma Ovarian Cancer BRCA2 0.05 
Pancreatic Cancer Ovarian Cancer BRCA2 0.05 
Bowel Cancer Brain tumours TP53 0.27 
Bowel Cancer Kidney Cancer MSH2 0.27 
Bowel Cancer Womb Cancer MSH6 0.27 
Lung Cancer Ovarian Cancer BRCA2 0.27 
Prostate Cancer Ovarian Cancer BRCA2 0.27 
Bowel Cancer Stomach Cancer CDH1,MSH2 0.53 
Breast Cancer Ovarian Cancer BRCA1,BRIP1,RAD51C 0.55 
Lung Cancer Melanoma BRCA2 0.61 
Lung Cancer Pancreatic Cancer BRCA2 0.61 
Melanoma Prostate Cancer BRCA2 0.61 
Prostate Cancer Pancreatic Cancer BRCA2 0.61 
Stomach Cancer Kidney Cancer MSH2 0.61 
Lung Cancer Prostate Cancer BRCA2 1 
















Table A.1.5: Regulatory SM-HCM. The first column represents cancer node one, 
the second column is the associated cancer node for cancers in column one, the 
third column is the shared gene for each of the two associated cancer nodes, the 
fourth column is the kappa agreement test results where low agreements <0.25, 
moderate agreement 0.25 to 0.50, high agreement 0.50 to 0.75 and the very high 
agreement 0.75 – 1. In total there are 14 genes and 11 primary cancer nodes. 
Cancer Node 1 Cancer Node 2 Gene Kappa 
Breast Cancer Bowel Cancer DNMT3B, ERBB4 -0.29 
Bladder Cancer Breast Cancer MDM2 -0.14 
Bowel Cancer Bladder Cancer PTGS2 -0.09 
Breast Cancer Prostate Cancer KLK3 -0.08 
Lung Cancer Bladder Cancer PTGS2 -0.02 
Breast Cancer Ovarian Cancer BRCA2 0.00 
Lung Cancer Breast Cancer DNMT3B, MIR30C1 0.00 
Lung Cancer Ovarian Cancer CHEK2 0.10 
Skin Cancer (Non 
Melanoma) Breast Cancer TP53 0.14 
Bowel Cancer Oesophageal Cancer PTGS2 0.19 
Bowel Cancer Womb Cancer MSH2 0.19 
Prostate Cancer Bowel Cancer MYC 0.22 
Lung Cancer Oesophageal Cancer PTGS2 0.24 
Lung Cancer Bowel Cancer 
DNMT3B, MLH1, 
PTGS2 0.26 
Bladder Cancer Oesophageal Cancer PTGS2 0.44 
Bladder Cancer Stomach Cancer OGG1 0.44 

















Table A.1.6: Gross Deletions SM-HCM. The first column represents cancer node 
one, the second column is the associated cancer node for cancers in column 
one, the third column is the shared gene for each of the two associated cancer 
nodes, the fourth column is the kappa agreement test results where low 
agreements <0.25, moderate agreement 0.25 to 0.50, high agreement 0.50 to 
0.75 and the very high agreement 0.75 – 1. In total there are 8 genes and 8 
primary cancer nodes. 
Cancer Node 1 Cancer Node 2 Genes Kappa 
Bowel Cancer Ovarian Cancer BRCA1 -0.07 
Breast Cancer Prostate Cancer CHEK2 0.00 
Prostate Cancer Ovarian Cancer BRCA2 0.14 
Bowel Cancer Breast Cancer BRCA1, TP73 0.25 
Breast Cancer Ovarian Cancer BRCA1, TP53 0.25 
Bowel Cancer Womb Cancer MSH2 0.38 
Bowel Cancer Bladder Cancer MSH2 0.38 
Melanoma Brain tumours CDKN2A 1.00 
Womb Cancer Bladder Cancer MSH2 1.00 
 
 
Table A.1.7: Small Indels SM-HCM. The first column represents cancer node 
one, the second column is the associated cancer node for cancers in column 
one, the third column is the shared gene for each of the two associated cancer 
nodes, the fourth column is the kappa agreement test results where low 
agreements <0.25, moderate agreement 0.25 to 0.50, high agreement 0.50 to 
0.75 and the very high agreement 0.75 – 1. In total there are 5 genes and 8 
primary cancer nodes. 
Cancer Node 1 Cancer Node 2 Gene Kappa 
Bowel Cancer Brain tumours MLH1 0.55 
Bowel Cancer Womb Cancer MSH6 0.55 
Breast Cancer Ovarian Cancer BRCA1 0.55 
Pancreatic Cancer Ovarian Cancer BRCA2 0.55 










Table A.1.8: Repeated Variations SM-HCM. The first column represents cancer 
node one, the second column is the associated cancer node for cancers in 
column one, the third column is the shared gene for each of the two associated 
cancer nodes, the fourth column is the kappa agreement test results where low 
agreements <0.25, moderate agreement 0.25 to 0.50, high agreement 0.50 to 
0.75 and the very high agreement 0.75 – 1. In total there are 2 genes and 3 
primary cancer nodes. 
Cancer Node 1 Cancer Node 2 Gene Kappa 
Breast Cancer Prostate Cancer CYP11A1 0 
Lung Cancer Prostate Cancer TERT 0 
 
Table A.1.9: Complex Rearrangement SM-HCM. The first column represents 
cancer node one, the second column is the associated cancer node for cancers 
in column one, the third column is the shared gene for each of the two associated 
cancer nodes, the fourth column is the kappa agreement test results where low 
agreements <0.25, moderate agreement 0.25 to 0.50, high agreement 0.50 to 
0.75 and the very high agreement 0.75 – 1. In total there are 1 genes and 2 
primary cancer nodes. 
Cancer Node 1 Cancer Node 2 Shared Genes Kappa 




















Table A.1.10: Gross Insertions SM-HCM. The first column represents cancer 
node one, the second column is the associated cancer node for cancers in 
column one, the third column is the shared gene for each of the two associated 
cancer nodes, the fourth column is the kappa agreement test results where low 
agreements <0.25, moderate agreement 0.25 to 0.50, high agreement 0.50 to 
0.75 and the very high agreement 0.75 – 1. In total there are 1 gene and 2 
primary cancer nodes. 
Cancer Node 1 Cancer Node 2 Shared Genes Kappa 










Table A.2.11: Chromosome gene mutations and associated cancers. The first column represents the chromosome number, the second column 
shows the genes symbols for gene on this particular chromosome, the third column contains the mutation class for genes on the chromosome 
in column one, and the fourth column shows is the cancers associated with that particular chromosome. 






Prostate cancer,Lung Cancer,Ovarian Cancer,Breast 
Cancer,Pancreatic Cancer,Leukaemia,Bowel 








Cancer,Bowel Cancer,Ovarian Cancer,Lung 









Deletion,Gross Deletions,Repeat Variations 
Lung Cancer,Thyroid Cancer,Bowel Cancer,Bladder 
Cancer,Lymphoma,Breast Cancer,Head and neck 
cancer,Leukaemia,Skin Cancer(Non Melanoma),Brain 








Deletion,Gross Deletions,Repeat Variations 
Leukaemia,Thyroid Cancer,Wilms 
Tumour,Lymphoma,Bowel Cancer,Bladder 
Cancer,Stomach Cancer,Prostate cancer,Mouth 
Oropharyngeal Cancer,Melanoma,Breast 







Melanoma,Prostate cancer,Bowel Cancer,Ovarian 
Cancer,Skin Cancer(Non Melanoma),Bladder 







Lymphoma,Lung Cancer,Bowel Cancer,Breast 
Cancer,Melanoma,Prostate cancer,Pancreatic 












Deletion,Small Indels,Small Insertions,Splicing 
Bowel Cancer,Head and neck cancer,Stomach 
Cancer,Lymphoma,Thyroid Cancer,Breast 
Cancer,Melanoma,Womb Cancer,Oesophageal 








Breast Cancer,Bowel Cancer,Leukaemia,Lung 







Pancreatic Cancer,Ovarian Cancer,Breast 














Bowel Cancer,Kidney Cancer,Prostate cancer,Ovarian 
Cancer,Breast Cancer,Skin Cancer(Non 
Melanoma),Stomach Cancer,Soft Tissue 
Sarcomas,Myxoma,Brain tumours,Lymphoma,Head 
and neck cancer,Leukaemia,Womb Cancer,Pancreatic 
Cancer 










Stomach Cancer,Head and neck cancer,Bladder 
Cancer,Lung Cancer,Bowel Cancer,Skin Cancer(Non 
Melanoma),Kidney Cancer,Prostate cancer,Brain 
tumours,Ovarian Cancer,Oesophageal Cancer,Soft 
Tissue Sarcomas,Parathyroid carcinoma 









Kidney Cancer,Bowel Cancer,Leukaemia,Breast 
Cancer,Stomach Cancer,Soft Tissue Sarcomas,Lung 
Cancer,Prostate cancer,Ovarian 










Breast Cancer,Womb Cancer,Ovarian Cancer,Lung 
Cancer,Prostate cancer,Stomach Cancer,Kidney 
Cancer,Bladder Cancer,Lymphoma,Brain 


















Bladder Cancer,Lung Cancer,Brain tumours,Stomach 
Cancer,Womb Cancer,Ovarian 
Cancer,Lymphoma,Melanoma,Leukaemia,Head and 
neck cancer,Breast Cancer,Oesophageal 








Prostate cancer,Lymphoma,Kidney Cancer,Breast 
Cancer,Lung Cancer,Leukaemia,Head and neck 
cancer,Bladder Cancer,Stomach Cancer,Oesophageal 





















Insertions,Small Indels,Gross Insertions 
Breast Cancer,Head and neck cancer,Bowel 










Bladder Cancer,Prostate cancer,Ovarian 
Cancer,Breast Cancer,Head and neck cancer,Bowel 
Cancer,Melanoma,Kidney Cancer,Thyroid 







Deletions,Gross Insertions,Repeat Variations 
Kidney Cancer,Melanoma,Brain tumours,Pancreatic 
Cancer,Lung Cancer,Leukaemia,Bowel Cancer,Breast 
Cancer,Prostate cancer,Skin Cancer(Non Melanoma) 
Ch X KDM6A,FAM123B,AR,SH2D1A,FMR1 Missense nonsense,Regulatory,Repeat 
Variations,Gross Deletions 
Wilms Tumour,Breast Cancer,Prostate 
cancer,Lymphoma,Ovarian Cancer 
















Table A.3.1: A sample table of 2,851 collected Missense/Nonsense mutation 
records, where the first column represents the genes , the second column the 
chromosome location, the third column the cancer disorder, the fourth column the 
encoded amino acid (the letters before the hyphen indicates the original codon 
sequence and the letters after the hyphen the incorrect codon sequence), the fifth 
column shows the encoded amino acid (the first three letters is the abbreviation 
of the original amino acid and the second three letters is the abbreviation for the 
iniquitous encoded amino acid; the numbers in the middle represent the peptide 
position of the changed amino acid, and the sixth column provides the PubMed 
literatures for each of the mutation record.  





ATM 11q22-q23 Breast_Cancer gAGC-CGC Ser788Arg Atencio (2001) Environ Mol Mutagen 
38, 200 
ATM 11q22-q23 Breast_Cancer tCAT-TAT His1380Tyr Atencio (2001) Environ Mol Mutagen 
38, 200 
ATM 11q22-q23 Breast_Cancer GAC-GGC Asp1467Gly Atencio (2001) Environ Mol Mutagen 
38, 200 
ATM 11q22-q23 Breast_Cancer cATT-GTT Ile2030Val Atencio (2001) Environ Mol Mutagen 
38, 200 










gTGT-CGT Cys61Arg Al-Mulla (2009) J Clin Pathol 62, 350 
BRCA
1 
17q21 Ovarian_cancer ACA-AGA Thr276Arg Akbari (2011) J Med Genet 48, 783 
BRCA
1 
17q21 Ovarian_cancer tGAT-AAT Asp330Asn Akbari (2011) J Med Genet 48, 783 
BRCA
1 













cAAG-CAG Lys918Gln Al-Mulla (2009) J Clin Pathol 62, 350 
BRCA
1 
17q21 Breast_Cancer tGGA-TGA Gly972Term Ahn (2007) Cancer Lett 245, 90 
BRCA
1 
17q21 Breast_Cancer TTG-TAG Leu1198Ter
m 
Ahn (2007) Cancer Lett 245, 90 
BRCA
1 










17q21 Ovarian_cancer AGG-ATG Arg1495Met Aziz (2001) Gynecol Oncol 80, 341 
BRCA
1 
17q21 Ovarian_cancer GAT-GTT Asp1692Val Akbari (2011) J Med Genet 48, 783 
BRCA
1 







aGAT-TAT Asp23Tyr Al-Mulla (2009) J Clin Pathol 62, 350 
BRCA
2 
13q12.3 Breast_Cancer CGT-CAT Arg2034His Awadelkarim (2007) Breast Cancer 
Res Treat 102, 189 
BRCA
2 
13q12.3 Ovarian_cancer aCTT-TTT Leu2686Phe Akbari (2011) J Med Genet 48, 783 
BRCA
2 
13q12.3 Breast_Cancer TATt-TAG Tyr2997Ter
m 
Ahn (2007) Cancer Lett 245, 90 
BRCA
2 
13q12.3 Ovarian_cancer GAT-GGT Asp3142Gly Akbari (2011) J Med Genet 48, 783 
CDH1 16q22.1 Gastric_cancer tGCA-ACA Ala617Thr Ascano (2001) Mod Pathol 14, 942 
RB1 13q14.2 Retinoblastoma AGG-AAG Arg46Lys Abouzeid (2009) Mol Vis 15, 771 
RB1 13q14.2 Retinoblastoma aGAA-TAA Glu280Term Babenko (2002) Mol Biol (Mosk) 36, 
623 
RB1 13q14.2 Retinoblastoma CTT-CAT Leu303His Babenko (2002) Mol Biol (Mosk) 36, 
623 
RB1 13q14.2 Retinoblastoma AAA-AGA Lys319Arg Babenko (2002) Mol Biol (Mosk) 36, 
623 
RB1 13q14.2 Retinoblastoma aCAG-TAG Gln436Term Abouzeid (2009) Mol Vis 15, 771 
RB1 13q14.2 Retinoblastoma TGCg-TGA Cys489Term Babenko (2002) Mol Biol (Mosk) 36, 
623 
RB1 13q14.2 Retinoblastoma TATa-TAA Tyr498Term Babenko (2002) Mol Biol (Mosk) 36, 
623 
RB1 13q14.2 Retinoblastoma gAAA-TAA Lys615Term Abouzeid (2009) Mol Vis 15, 771 
RB1 13q14.2 Retinoblastoma aGAA-TAA Glu746Term Babenko (2002) Mol Biol (Mosk) 36, 
623 
RB1 13q14.2 Retinoblastoma TTA-TAA Leu797Term Ata-ur-Rasheed (2002) Ophthalmic 
Genet 23, 121 
RB1 13q14.2 Retinoblastoma TTCc-TTA Phe845Leu Babenko (2002) Mol Biol (Mosk) 36, 
623 
RET 10q11.2 Thyroid_cancer cAAG-GAG Lys666Glu Ahmed (2005) J Mol Diagn 7, 283 
MLH1 3p21.3 Colorectal_cancer GTG-GAG Val49Glu Auclair (2006) Hum Mutat 27, 145 
MLH1 3p21.3 Colorectal_cancer AGCa-AGA Ser106Arg Auclair (2006) Hum Mutat 27, 145 
MLH1 3p21.3 Colorectal_cancer GTT-GAT Val113Asp Auclair (2006) Hum Mutat 27, 145 
MLH1 3p21.3 Colorectal_cancer gGGG-CGG Gly454Arg Auclair (2006) Hum Mutat 27, 145 
MLH1 3p21.3 Colorectal_cancer GCC-GAC Ala586Asp Auclair (2006) Hum Mutat 27, 145 
MSH2 2p22-p21 Colorectal_cancer cACA-GCA Thr33Ala Auclair (2006) Hum Mutat 27, 145 
MSH2 2p22-p21 Colorectal_cancer TAT-TGT Tyr43Cys Auclair (2006) Hum Mutat 27, 145 
MSH2 2p22-p21 Colorectal_cancer CTT-CGT Leu187Arg Auclair (2006) Hum Mutat 27, 145 
MSH2 2p22-p21 Colorectal_cancer CGG-CAG Arg243Gln Auclair (2006) Hum Mutat 27, 145 
MSH2 2p22-p21 Colorectal_cancer TCT-TGT Ser323Cys Akiyama (1997) Biochem Biophys 
Res Commun 236, 248 
MSH2 2p22-p21 Colorectal_cancer CTT-CCT Leu341Pro Auclair (2006) Hum Mutat 27, 145 
MSH2 2p22-p21 Colorectal_cancer tGGT-TGT Gly548Cys Auclair (2006) Hum Mutat 27, 145 
MSH2 2p22-p21 Colorectal_cancer tGAA-AAA Glu561Lys Auclair (2006) Hum Mutat 27, 145 
MSH2 2p22-p21 Colorectal_cancer AAAg-AAC Lys627Asn Auclair (2006) Hum Mutat 27, 145 
TP53 17p13.1 Breast_&_Colore
ctal_Cancer 
GGC-GAC Gly244Asp Achatz (2007) Cancer Lett 245, 96 
TP53 17p13.1 Choroid_Plexus_
Tumours 
AAC-ATC Asn131Ile Agarwalla (2008) Pediatr Neurosurg 
44, 501 









Table A.3.2: The 21 altered amino acid network tables, where the first column is 
node one gene, the second column is the associated node two gene, the third 
column is the cancer disorder name, the fourth column is a match column where 
‘0’ is equal to identical altered amino acid in both genes, ‘1’ is the identical codon 
change in both genes and ‘2’ is the identical altered amino acid occurs in same 
peptide position of the two altered amino acid. Fifth and sixth columns are the 
encoded codon and amino acid for node gene one, and the seventh and eight 
columns are the encoded codon and amino acid for node gene two.  
Alanine 
Node1 Node2 Cancer Match Node1 codon 
change 




Node2 Amino acid 
changes 










































































































































































































































































































































































































































ERCC5 ERCC3 Lung Cancer 0 aACG-GCG Thr971Ala cACT-GCT Thr232Ala 














































































































































Node1 Node2 Cancer Match Node1 codon 
change 




Node2 Amino acid 
changes 















































































BRCA2 BUB1B Leukaemia 1 CAA-CGA Gln1396Arg CAA-CGA Gln349Arg 























































































































































































































CHEK2 TP53 Breast Cancer 0 CCT-CGT Pro85Arg cTGC-CGC Cys242Arg 
































































CHEK2 BRCA1 Ovarian 
Cancer 


































ERCC2 ERCC3 Lung Cancer 0 CGCt-CGA Arg156Arg AAG-AGG Lys449Arg 























































EXO1 PMS2 Bowel Cancer 0 CTC-CGC Leu410Arg CCT-CGT Pro404Arg 






























































































MSH2 MLH1 Gastric Cancer 0 CTA-CGA Leu173Arg AGCa-AGG Ser106Arg 



















































































































































































































































































PARP1 TP53 Breast Cancer 0 cCGA-AGA Arg452Arg cTGC-CGC Cys242Arg 





















































































































































PTEN TP53 Breast Cancer 0 AGTg-AGG Ser207Arg cTGC-CGC Cys242Arg 
Asparagine 
Node1 Node2 Cancer Match Node1 codon 
change 




Node2 Amino acid 
changes 







































































































































































































































































































TP53 BARD1 Breast Cancer 0 aGAC-AAC Asp281Asn AAAt-AAT Lys312Asn 
Glutamate 
Node1 Node2 Cancer Match Node1 codon 
change 




Node2 Amino acid 
changes 










































































































































EXO1 PMS2 Bowel Cancer 1 GGA-GAA Gly759Glu GGA-GAA Gly207Glu 













































































































































Node1 Node2 Cancer Match Node1 codon 
change 




Node2 Amino acid 
changes 













































































































































































































































































































CHEK2 TP53 Breast Cancer 0 gAGG-GGG Arg117Gly GTG-GGG Val122Gly 






























































































































































































































Node1 Node2 Cancer Match Node1 codon 
change 




Node2 Amino acid 
changes 





























































































































































































































CDKN2A CDK4 Melanoma 0 cGAT-CAT Asp125His CGT-CAT Arg24His 
































































































































































MUTYH APEX1 Bowel Cancer 1 CAGg-CAC Gln498His CAGa-CAC Gln51His 






























OGG1 XPC Bowel Cancer 0 CGC-CAC Arg154His CGT-CAT Arg492His 
Isoleucine 
Node1 Node2 Cancer Match Node1 codon 
change 




Node2 Amino acid 
changes 

















































































































































































































































































MET PIK3R1 Bowel Cancer 0 ACT-ATT Thr1010Ile ATGt-ATA Met326Ile 





















































































































































































PMS2 MSH3 Bowel Cancer 0 ATGa-ATA Met622Ile cGTA-ATA Val79Ile 
TP53 PML Breast Cancer 0 tGTC-ATC Val97Ile ACC-ATC Thr28Ile 





Node1 Node2 Cancer Match Node1 codon 
change 




Node2 Amino acid 
changes 














































































































































































































































































































































































PTEN TP53 Breast Cancer 0 AGA-AAA Arg161Lys aGAG-AAG Glu285Lys 
Methionine 
Node1 Node2 Cancer Match Node1 codon 
change 




Node2 Amino acid 
changes 

































































BRCA2 BRCA1 Ovarian 
Cancer 













































































































































Node1 Node2 Cancer Match Node1 codon 
change 




Node2 Amino acid 
changes 
























































































































































































































































































































































































































































































































































Node1 Node2 Cancer Match Node1 codon 
change 




Node2 Amino acid 
changes 




















CHEK2 BRCA2 Prostate 
Cancer 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Node1 Node2 Cancer Match Node1 codon 
change 




Node2 Amino acid 
changes 





























































































































































































































































































































































































































































































Node1 Node2 Cancer Match Node1 codon 
change 




Node2 Amino acid 
changes 
























































































































BRCA2 BRCA1 Prostate 
Cancer 
0 TGC-TAC Cys1290Tyr tCAC-TAC His448Tyr 

















































































































Node1 Node2 Cancer Match Node1 codon 
change 




Node2 Amino acid 
changes 
AR RNASEL Prostate 
Cancer 
0 gACC-TCC Thr559Ser gGGC-AGC Gly59Ser 

















































BRCA1 MSH3 Bowel Cancer 0 gTGT-AGT Cys39Ser tCCA-TCA Pro681Ser 




















































BRCA1 MLH1 Bowel Cancer 
  














































































































































































































































































































































































































































AAT-AGT Asn41Ser  


































































































MET CDH1 Stomach 
Cancer 

























































































































































































































































































XRCC2 RAD51C Breast_Cancer 0 tGCC-TCC Ala16Ser TTA-TCA Leu219Ser 
Aspartate 
Node1 Node2 Cancer Match Node1 codon 
change 




Node2 Amino acid 
changes 




















































































































































































































































































































Node1 Node2 Cancer Match Node1 codon 
change 




Node2 Amino acid 
changes 






































































































































































































































































































































































































CHEK2 TP53 Breast Cancer 0 cCGT-TGT Arg346Cys gCGC-TGC Arg181Cys 































































































































OGG1 XPC Lung Cancer 0 TCC-TGC Ser326Cys tCGT-TGT Arg671Cys 
TP53 MSH2 Gastric Cancer 0 gCGC-TGC Arg283Cys TAT-TGT Tyr408Cys 
XRCC2 RAD51C Breast Cancer 0 TGGc-TGT Trp231Cys tCGT-TGT Arg249Cys 
Glutamine 
Node1 Node2 Cancer Match Node1 codon 
change 




Node2 Amino acid 
changes 
AR SMAD4 Breast Cancer 0 CGA-CAA Arg608Gln CAGg-CAA Gln450Gln 










































































































































































































































BRCA2 BRCA1 Ovarian 
Cancer 












BRCA2 BRCA1 Prostate 
Cancer 
0 CCA-CAA Pro2347Gln CGA-CAA Arg1203Gln 

























CHD1L XRCC1 Lung Cancer 0 CACc-CAG His350Gln CGG-CAG Arg399Gln 
















































































































































MUTYH MSH6 Bowel Cancer 0 CGG-CAG Arg184Gln CTG-CAG Leu1354Gln 


























PMS2 MSH3 Bowel Cancer 1 CGG-CAG Arg20Gln CGG-CAG Arg949Gln 


















Node1 Node2 Cancer Match Node1 codon 
change 




Node2 Amino acid 
changes 
AR RNASEL Prostate 
Cancer 
0 CGC-CTC Arg727Leu tATC-CTC Ile97Leu 






































































































































































































































































































































































































































































































































FANCD2 NBN Breast Cancer 0 CTTt-CTG Leu1366Leu CCG-CTG Pro266Leu 










































































































































































































Node1 Node2 Cancer Match Node1 codon 
change 




Node2 Amino acid 
changes 




















































































































































































































CHEK2 BRCA2 Ovarian 
Cancer 


























CHEK2 BRCA2 Prostate 
Cancer 
0 cATC-TTC Ile251Phe cCTT-TTT Leu3055Phe 











































CHEK2 BRCA1 Ovarian 
Cancer 



















































Node1 Node2 Cancer Match Node1 codon 
change 




Node2 Amino acid 
changes 












BRCA1 MLH1 Breast Cancer 1 aCGG-TGG Arg1699Trp cCGG-TGG Arg389Trp 
BRCA1 MSH2 Bowel Cancer 0 aCGG-TGG Arg1699Trp tGGG-TGG Gly164Trp 


































MSH6 MSH2 Bowel Cancer 0 gCGG-TGG Arg772Trp tGGG-TGG Gly164Trp 
BRCA1 MSH3 Bowel Cancer 0 aCGG-TGG Arg1699Trp TTG-TGG Leu911Trp 






























BRCA2 BRCA1 Ovarian 
Cancer 





























CHEK2 TP53 Breast Cancer 1 tCGG-TGG Arg3Trp aCGG-TGG Arg267Trp 
MSH3 MSH2 Bowel Cancer 0 TTG-TGG Leu911Trp tGGG-TGG Gly164Trp 
BRCA1 MLH1 Bowel Cancer 1 aCGG-TGG Arg1699Trp cCGG-TGG Arg389Trp 
Valine 
Node1 Node2 Cancer Match Node1 codon 
change 




Node2 Amino acid 
changes 


















































































































































































































































































































































































CHEK2 TP53 Breast Cancer 0 aATT-GTT Ile189Val GCC-GTC Ala138Val 


































































































































































































































































































































































RAD23B XPC Lung Cancer 0 GCT-GTT Ala249Val GCG-GTG Ala499Val 
TP53 AURKA Breast Cancer 0 GCC-GTC Ala138Val GCA-GTA Ala213Val 
XRCC2 RAD51C Breast Cancer 0 aATT-GTT 
tTTT-GTT 
Ile95Val 
Phe270Val 
GGT-GTT 
aTTA-GTA 
Gly125Val 
Leu262Val 
 
 
 
 
